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Abstract 
The biotech sector is highly specialized, with long development time lines, high risk and high 
investment financing requirement, however with high returns. At a global scale, the USA and 
Europe are the most important markets, accounting for half of the global biotech patents. In 
2012, the USA held 46.6% of the global sales in this sector with the European Union at 28.5%, 
Japan at 8.4% and BRICS at 3.4%. Much of the growth (29.3%) is however, expected in 
emerging markets. The South African government has invested an amount of approximately 
R1 billion in the period from 2003 to 2011 in the Biotechnology start-ups. It is not clear whether 
a return on this investment has been realized. Thus, the aim of this work is to investigate what is 
the investment performance of the South African Biotechnology industry, what funding models 
have been used and suggest models that would be appropriate for Biotechnology startups to 
result in an improved investment performance. The methods applied included reviewing various 
published journal articles, industry reports and lastly having structured expert interviews with 
major funders in the South African Biotechnology industry that is, the IDC, TIA, the dti and DST. 
The findings indicate that when compared to the development markets, the composition of the 
SA biotechnology sector lags behind in terms of the number of companies that are in existence, 
publically listed companies, revenue generated by companies in this sector and number of jobs 
created. It is evident that although government funding and percentage national GDP spend on 
R&D in this sector is on par with that of India and Brazil, the lack of private sector funding is 
much more pronounced in South Africa. In addition, the market size, industry revenues and 
profits generated in SA are much less than those of its emerging market counterparts. 
Furthermore, in addition to the financing environment that is not broad enough, there are critical 
structural elements such as the involvement of universities, alliances with large corporates and 
the role of the stock market in raising capital that need to be addressed. It is thus, suggested 
that the South African government reviews its current funding models in an effort to realize a 
return on its investments. Two models are proposed in this work. Firstly, government-private 
sector matching funds linked to an incubator and secondly, increasing the pool of funds by 
accessing patient capital and structuring it as VC –type fund. These models have been very 
successful in yielding returns in other markets and improving the impact of the sector. 
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Chapter 1: Introduction 
1.1 Introduction 
 
This chapter introduces the thesis by providing the context of the study as well as the research 
objectives and the research problem that rationalizes this research. The chapter is organized as 
follows. Section 1.2 presents the research context. Section 1.3 discusses the research problem. 
Section 1.4 presents the research questions. Section 1.5 presents research objectives. Section 
1.6 identifies the gap in the literature and lastly section 1.7 presents the organization of the 
thesis and the chapter summary concludes the chapter.  
1.2 Context of the study 
 
Biotechnology refers to a wide range of life science technologies whose aim is to understand, 
modify or direct the function of a wide set cellular functions or DNA to attain a product with 
applications in human or animal health care applications, agriculture, industry and the 
environmental sector. The biotechnology industry sector entails life sciences technology 
development by both small and large enterprises or research & development (R&D) institutions 
in cross cutting fields of health, agriculture, food processing, industry and environment 
management with the objective of addressing a social, health or industrial needs in the market 
(Prevezer, 2001). This level of systems integration and application of various DNA based 
technologies to develop specific products we see in the field of Biotechnology is referred to as 
the “third-generation biotechnology”. The “first-generation biotechnology” was mainly driven by 
fermentation technologies in the food and agriculture sectors. This was followed by the “second 
generation biotechnology” which developed as an outgrowth of the fermentation technologies by 
providing an understanding of how microorganisms can be applied in the sector (Pandya, 2012). 
 
Typical biotechnology process or products include, beverage fermentation, food processing, 
diagnostic kits, vaccines, to name a few. In South Africa, biotechnology has played a significant 
role in the fermentation process, where products such a beer, bread, wines etc. are highly 
depended on technologies that have their origins in the biotechnology sector. Thus this sector, 
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has led to the establishment of companies such as South African Breweries, numerous wineries 
and various yeast production companies that are critical to the economy of South Africa. 
Other biotechnologies that such as Bacteria and virus manipulation processes, have played a 
critical role in development technologies and methods to produce, probiotics (which are used in 
various dairy products), vaccines which are critical to health of South Africans. With the recent 
move towards a greener, sustainable living, biotechnology is playing a key role in the production 
of biofuels which have revolutionarised the manner in which agriculture waste and other carbon-
based waste is managed. Waste is becoming a commodity, whose value is greatly enhanced 
through biotechnology based processes, by converting it to energy and recycled products. The 
examples provided here, illustrate that a successful biotechnology sector has the potential to 
impact positively on the social and economic development of a country. It can be exploited to 
address many challenges facing a country such as food security, through the development of 
genetically modified crops that a more robust and have added nutritional benefits (Solem and 
Gaivoronskaia, 2005), affordable healthcare through locally manufacturing vaccines, point of 
care diagnostics, various therapies (Pouris and Pouris, 2009), and lastly providing 
environmental sustainability through waste recycling, waste water recycling and clean energy 
production technologies (Solem and Gaivoronskaia, 2014). 
 
The impact of Biotechnology is not only limited to a single industry or product line, but spans 
across the sectors mentioned above. Biotechnology provides the potential to transform 
traditional industries into advanced, high technology and systems based industries. Examples of 
these are the sensor technologies in agriculture and manufacturing, personalized medicine in 
the pharmaceuticals sector and environmental condition tolerant plant strains in the food sector 
(Pandya, 2012). As the world population continues to grow, pressure is exerted on natural 
resources and with the aging populations faced with complex diseases, the Biotechnology 
sector emerges as one of the critical sectors that will affect and contribute to a number of 
industries that include sustainable environment, energy security, water security, food security, 
agriculture, pharmaceuticals, chemicals, mining as well as the health care sector for both animal 
and human health (Solem and Gaivoronskaia, 2005; Ernest and Young, Global Biotechnology 
Report, 2013). Key sectors of the biotechnology industry include biopharmaceuticals, molecular 
diagnostics, agriculture, nutraceuticals, biofuels, the environment and biosecurity. Apart from 
developing drugs that can assist in resolving socio economic problems of a county, small 
biotechnology firms can contribute to the economic development of the country.  
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The benefits in this industry are generally realized by those countries that have the requisite 
biotechnology skills, large commercial industry that is depending on continuous development of 
innovative products and services emerging from the sector and investment environment for 
technology commercialization. Thus, highly developed countries such as the USA, UK, France, 
Germany, Switzerland, Sweden and Japan are the present Biotechnology super powers. 
Although the applications of Biotechnology are also concentrated in these countries, they are 
now extending to the developing countries, where significant benefits are being realized. Most 
biotechnology products in these developing countries are in the form of imported products, 
however it is expected that in sectors such as agriculture and energy, where countries such as 
South Africa have know-how and resource benefits, the dependency on imported products will 
be minimized with time (Caldwell, 1988). 
 
Biotechnology industry is characterized by high cost and high risk innovation and has emerged 
as a prototype industry for commercialization of scientific ideas and provides lessons for the 
processes and mechanisms involved in technology commercialization (Prevezer, 2001). 
Development of biotechnology products, particularly in the pharmaceutical sector has been 
characterized by extremely long development times and high development costs. Such delays 
are due in part to the stringent regulatory oversight exercised over the safety of new drugs, 
foods, biologics, and over environmental release of new organisms (Pandey, 2012). An 
important distinction of the biotechnology industry is that start-up companies in this sector are 
heavily reliant on the large established firms within existing industrial sector as their market / 
users. Furthermore, the overlap between the health biotechnology sector and the 
pharmaceuticals sector is increasingly becoming strong, thus the beneficial industry in health 
biotechnology tends to large pharmaceutical companies. These features thus lead to the 
development of industry clusters in regions such as California (San Diego, San Francisco etc) 
which were critical enablers of commercialized biotechnology industry. (Prevezer, 2001) 
 
The biotechnology industry originated in the USA Universities, primarily in the state of California, 
where researchers exploited the commercialization of knowledge and tools in the DNA 
technologies. Many of the initial biotechnology firms were established by University scientist. 
One of the most successful was Genentech which was established by a scientist from University 
of California, San Francisco (Prevezer, 2001). While small firms were the dominant force in the 
initial development of the biotechnology industry, larger USA firms joined the market in the early 
1980s and contributed to further development in many ways, including being merger and 
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acquisition (M&A) or joint venture (JV) partners to these smaller firms. Lazonick and Tulum 
(2001) report that in the between 1999-2001 approximately $10 billion was spent on corporate 
and small firm partnering in the US biotech Industry, an amount which rose to approximately 
$17.2 billion in the period between 2005-2006. These alliances typically included contract R&D 
for drug development in exchange of some IP rights and marketing rights upon drug approval. 
The Ernst &Young Global Biotechnology Industry report (2013), indicates that on average, in the 
USA, during the first decade of a biotechnology firm’s existence, 10% of the funding comes from 
venture capital, 50% from alliances with large companies and 40% from public equity markets. 
Many more examples like Genentech, such as Amgen, and Biogen-Idec now exist, with the 
USA having the largest concentration of biotechnology companies at 2356 in 2011 followed by 
France at 1300 firms (Key Biotechnology indicators, OECD, 2011). The Industry has exhibited a 
strong global presence and is increasingly expanding, with over $200 billion in revenues in 
2009. Over the last decade, the industry has posted double digit growth (Lazonick and Tulum, 
2011). 
 
There are very few American-type start-up biotechnology ventures, which have the backing of 
financing institutions, extensive government investment into R&D exceeding 2% of the national 
GDP, and the requisite culture to foster entrepreneurship. More specifically countries such as 
Brazil, Russia, India, China and South Africa have Gross Domestic Expenditure on Research 
and Development (GERD) at 1.16%, 1.09%, 0.8%, 1.84% and 0.76% respectively. These 
expenditures are much lower than those in developed countries such as Japan, the UK and 
USA with GERD levels of 3.39, 1.77 and 2.77 respectively (The 2013 Global Innovation Index 
report, 2013). This report also indicated that in line with the low GERD in South Africa, the 
government contribution to business expenditure on R&D is only about 0.05% of GDP, which is 
very low when compared to Russia, Brazil and China, which have contribution of 0.41%, 0.15% 
and 0.10% respectively. The R&D tax incentive is another government instrument used in 
various countries to stimulate private sector research and development. In South Africa with a 
corporate income tax rate of 28%, most companies benefit from a tax reduction of 14% of the 
qualifying R&D expenditure. What the 2012 Global Survey of R&D Tax by Deloitte indicated that 
in South Africa, R&D tax incentives beneficiaries are large companies with revenue in excess in 
100 million Rand. When compared to its BRICS counterparts, the South African allowed 
deduction of 15% is low since these countries have R&D tax incentives in the region of 20% 
(2012 Global Survey of R&D Tax). Furthermore, many countries experience a lack of both 
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entrepreneurship and venture capital, a rigid labor market characterized by the need for stable, 
life-long employment culture (Yosikawa, 1990; Albader et al., 2009; Abuduxikie et al., 2012).  
 
South Africa’s GERD is comparable to that of India; however India’s Biotechnology industry is 
much more advanced with about 200 companies and is performing much better in that it holds 
about 2% market share of the global Biotechnology industry compared to South Africa with 60 
companies (Key Biotechnology Indicators, OECD, 2011). Thus, this begs the question that why 
is South African’s Biotechnology Industry lagging behind that of its BRICS counterparts.  
1.3  Research problem 
The South African government through its various agencies has invested an amount of 
approximately R1 billion in the period from 2003 to 2011 in the Biotechnology start-ups (National 
Advisory Council on Innovation, 2013 Report). It is not clear whether a return on this investment 
has been realized, however there is non-existent contribution of the biotechnology sector to the 
national GDP and the number of biotechnology SME’s since 2005 has been ranging between 
70-100 companies (Al-Bader et al., 2009), showing little if any growth. Therefore, it is not clear 
whether the problem lies with the funding method used or the nature of the industry. Thus, the 
aim of this work is to investigate what the investment performance of the South African 
Biotechnology industry, what funding models have been used and suggest which model or 
models would be appropriate for Biotechnology startups that will result in better investment 
performance. 
1.4 Research questions 
1. How has the South African Biotechnology Industry performed between 2005-2013 
compared to other markets? 
2. What funding model have to date been employed in South Africa compared to other 
markets? 
3. What is the appropriate funding model that is required to improve the industry 
performance? 
1.5 Research objectives 
 To determine the investment performance of Biotechnology companies in South Africa. 
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 To make a comparative performance analysis of the South African Biotechnology 
Industry and developed markets. 
 To investigate the appropriate financing model for South Africa that would result in 
significant growth  
1.6  Research gap 
 
The biotech sector is critical to the innovation systems of the many countries especially South 
Africa because of its socio-economic challenges including unequal distribution of income as 
indicated by the GINI co-efficient of 0.63 (www.indexmundi.com, accessed on the 24 September 
2014), high disease burden (WHO health report 2011), service delivery challenges in the water 
and sanitation, health and education sectors. All these factors and many others led to the South 
African government through the Department of Science Technology and the Department of 
Trade and Industries setting up policies and programs to invest and financially support 
Biotechnology startup companies that develop solutions to address these challenges. 
Biotechnology presents an avenue for the country to innovate in the fields of agriculture, health 
sciences, food production and lastly water services (Pouris, and Pouris, 2009). 
 
In 2003, 107 biotechnology companies were identified, with 47 being classified as “modern 
biotechnology core” companies (defined as those who are using at least one biotechnology 
related technique and whose main economic activity is biotechnology.) and 59 as active 
Biotechnology companies (i.e these companies either perform R&D in biotechnology or 
produces and sells biotechnology products) were identified in South Africa (National 
Biotechnology Survey, 2003). The National Biotechnology audit of 2007 established that in 2007 
of the total number had declined to 78, with 38 companies ”core” biotechnology companies 40 
classified as active Biotechnology companies at the time of the audit. These companies 
employed not more than 50 employees each. Of these companies 37% were spin-offs from 
research institutions, 28% from universities, the rest were start-ups. About 39% of the 
companies in the human health sector, 38% in agriculture sector, which includes animal health, 
food and beverage and environment. The support services comprised the balance of 23%. 
 
The Biotech industry in South Africa is highly fragmented, but shows significant growth 
prospects due to a number of factors such as world class researchers and research institutions, 
a healthy pipeline of innovative biotechnologies, unraveled indigenous knowledge system, a 
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large genetic human diversity pool, access to a large patient population for both communicable 
and non-communicable diseases and lastly and a know how in the manufacturing sector (Daar 
et al., 2002). The sector is heavily concentrated in the Western Cape and the Gauteng 
provinces with both provinces having 78% of biotechnology companies, followed by Kwazulu 
Natal with 17% (National Biotechnology survey, 2003). Notably, these provinces are home to 
some of the top universities in the country; with Gauteng being the economic engine of the 
country with an inhabitant population of 12.3 million people (South African Statistic, 2012). The 
South Africa government remains a major role player in this sector, where the majority of the 
funding that these enterprises receive is through publically funded institutions such as the 
Technology Innovation Agency (TIA), Industrial development Corporation (IDC) which amounted 
to R216 million between 2003 and 2006 (National Biotechnology Audit, 2007). Secondly, the 
country has a solid culture of patent protection in line with international standards. Through the 
IPR act, the intellectual property emanating from publically financed research is channeled 
towards benefiting the country through commercializing the respective technologies (IPR Act, 
2008).  
 
Although the government is playing a pivotal role in funding Biotechnology firms, the problem is 
that there is still a huge gap in financing start-up biotech companies. Granted, this problem is 
not unique to the Biotechnology sector, and is experienced across various industries (Al-Bader 
et al., 2009) but given the socio-economic and health challenges of South Africa, an in-depth 
research is required for us to understand how to grow the industry and establish the best 
funding model for biotech startups that will result in economically contributing firms. The general 
view is that, more Biotechnology start-ups would contribute to the alleviation of chronic South 
African social and health related problems while at the same time addressing economic issues 
including high levels of unemployment. Due to the high risk and high cost associated with the 
Biotechnology Industry, the financing of a biotechnology start-up, unlike various other types of 
startup enterprises, requires a significant amount of the investment capital that makes this 
sector, inaccessible for many, particularly the risk averse type of investors. The typical costs 
associated with funding a Biotechnology start-up in South Africa, i.e post the R&D investment 
costs generally amount to R106 million, and the success rates of the innovations are relatively 
low making Biotechnology a high investment and high risk sector (Mussam and Singer, 2010). 
 
As it is detailed in the thesis, much work has gone into unpacking the recent performance of the 
biotechnology industry in emerging markets such as India (Association of Biotechnology Led 
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Enterprises, 2012 report) and Brazil (Resende 2012) which have similar socio-economic and 
relatively small Biotechnology markets as South Africa. These reports highlight the performance 
of the industry on a local and global scale and suggest approaches that would lead to better 
financial performance of the industry. Such work is currently not available for the South African 
Biotechnology sector, and thus with this background, the aim of this research is to investigate 
the performance of the South African Biotechnology industry to date and propose an 
appropriate funding mechanism that would result in the growth of this sector. 
1.7 Organization of the research 
 
The study will be structured in five chapters as follows: Chapter 2 provides detailed literature 
review of the financing mechanisms for small enterprises. This chapter covers literature on 
various aspects of biotechnology including the characteristics of Biotechnology industry, the role 
of intellectual property and issues relating to valuation of Biotech companies, and lastly 
addresses the funding challenges encountered by Biotechnology start-ups and other SME’s in 
general. Chapter 3 discusses the methodologies that are applied to address the objectives of 
this research stated above. These include the methods applied in developing the financing 
model that will be proposed. Chapter 4 presents the research results. Chapter 5 presents 
discussion and concludes the thesis. 
 
Chapter 1 has presented the overall context of the study, the research gaps and the overarching 
research question which is, “what is the investment performance of the Biotechnology industry 
and what is the best funding model for Biotechnology startups that will result in better 
investment performance?”. The global context for both developed and developing biotechnology 
industries was presented, where it was apparent that government, corporates and financiers 
play a vital role in unlocking the economic benefit of this industry.  To filly unpack this research 
question, the next chapter will provide an in-depth review of the Biotechnology industry, 
focusing on characteristics of the industry and typical financing mechanisms for the industry. 
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Chapter 2 Literature Review 
2.1  Introduction 
The chapter reviews the role and significance of the biotechnology sector in both developed and 
developing countries focusing on the South African context and the impact it can have on the 
socio economic factors. This area is covered in section 2.2. Section 2.3 reviews a critical aspect 
of factors that make the industry successful, focusing on the role of governments in both 
developed and emerging markets in supporting the growth of the industry. The funding 
mechanisms relevant for the sector are discussed in section 2.4, with section 2.5 focusing on 
evaluating the performance and impact of the investment funds that have been made in the 
respective countries. In financing biotechnology firms, a critical aspect is valuation of the 
companies and due to these firms mainly having intangible assets, valuation techniques for 
such assets are reviewed in detail in section 2.6. The final section of this chapter looks at 
biotechnology SME’s and the economic impact they could have that are also evident in SME’s 
in various industries.  
2.2 Characteristics and role of Biotechnology industry 
Biotechnology industry is characterized by high cost and high risk innovation. Development of 
biotechnology products, particularly in the pharmaceutical sector has been characterized by 
extremely long development times of approximately 12 years and high development costs in the 
region of $100 Within the Biotechnology sector, the biopharmaceuticals industry has been the 
largest sector worth $80 billion in 2010, followed by nutraceuticals and functional foods at 
$50billion, sustainable environment technologies ($30 billion), biosecurity ($7 billion), biofuels 
($6 billion) and molecular diagnostics at $3.5billion (Ernest and Young, Global Biotechnology 
Report, 2013). The US Food and Drug Administration (FDA) approved the first biotechnology 
drug in 1982, since then about 254 biopharmaceuticals have been approved for 385 clinical 
indications. More biopharmaceuticals are in clinical development for indications such as 
cancers, cardiovascular disease, AIDS and arthritis, attracting over $24.8 billion in financing. 
million R&D expenditure, thus it requires “patient capital” investment (Pandey, 2012).  
A typical scenario in this industry is that governments play a significant role in the early stages 
of development, where public-private partnerships with venture capital firms and private equity 
firms emerge. The partnership is critical in that government provides that initial R&D investment 
as it was seen with the National Institutes of Health (NIH) in the US and the financial institutions 
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provide the start-up investments, managerial skills, technical expertise and business networking 
to high technology start-ups (Papadimitriou and Mourdoukoutas, 2002).  
 
The industry is distinctive for its scientific R&D reliance but also for its small firm structure (i.e 5-
20 employees). A typical small biotechnology company has little prospects of producing a 
commercial product in the immediate future. A key characteristic of biotechnology firms is the 
intensive investment in R&D, where compared to other industries such as automobile, steel 
production and energy which spend 5% of their revenues on R&D, Biotechnology firms spend 
approximately 15-30% on R&D. In the early stages of development, some firms even spend 
more than their revenues on R&D which may at times lead to them not reaching commercial 
stage if the required funding is not accessed (Tan and Lim, 2007). The authors also indicate that 
on average, R&D accounts for 36% of the total operating cost for these firms. Once the R&D 
costs are covered, the next hurdle of product development and business development fund 
raising begins, whereby for the former, angel investors and venture capital financing is the 
available type of financing, whereas for the business development and enterprise growth, 
funding requirements grow exponentially and these funds generally come from financial 
markets, i.e Initial Public Offering (IPO) or from an M&A (Papadimitriou and Mourdoukoutas, 
2002). Most Biotechnology firms fail in the stage between late stage R&D and early stage equity 
financing. What is typically observed is that in markets such as the US, where bankers are very 
familiar with this industry and are more risk tolerant, the failure rate is lower than counties such 
as the UK, Sweden where venture capital financing is more available for the later stage of the 
firms development (Papadimitriou and Mourdoukoutas, 2002, Autant-Bernard et al., 2006). The 
maturity of the stock markets and the exchange requirements by the respective stock markets 
play a major role in this late stage funding phase. For example in the USA a start-up can raise 
$25 million through the NASDAQ and pay fees of up to $2 million for the exchange 
requirements (Prevezer, 2001), yet in emerging markets where the stock exchanges are not at 
the same size as the NASDAQ, IPO listings are not so successful (Ahn et al., 2012).  
M&A, JVs and IPOs are typical exit strategies for many venture-backed biotech firms; however, 
investors are exploring quicker exits versus the typical 10-12 years. Firstly, investors are 
investing in later stage products and management teams with commercial experience. The 
second approach entails founding a start-up jointly with a large corporate companies i.e big 
pharma company, a big energy company or agriculture firms, who would then take an option to 
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acquire the start-up following certain milestones being met. Lastly, the third model entails-asset 
centric financing models, which facilitate efficient product development (Lazonick and Tuum, 
2011). 
In many countries that are leading in the Biotechnology sector, one of the critical aspects that 
have led to the growth of this industry is regional clusters. This is observed in regions such as 
California, Massachusetts (Prevezer, 2001), Paris and Bordeaux (Autant-Bernard et al., 2006) 
to name of few. These regional level clusters tend to facilitate local interactions, provide 
collaborative infrastructure as well as host institutions such as business incubators and regional 
funding agencies to fuel growth. Within a country, these regions tend to compete to attract start-
ups to the area, increase the technology competitiveness of the region, develop regional 
specialization and attract large corporates who are seeking for innovations and knowledge 
based skills to support their innovation endeavors (Autant-Bernard et al., 2006). In the drive to 
determine what makes these regional clusters successful, Autant-Bernard et al. (2006) explored 
the French Biotechnology industry and identified that factors such as 1) the proximity to sources 
of knowledge, i.e universities, centers of excellence, and science councils, 2) the absorptive 
capacity of the region to effect local collaborations, accommodate firms of different sizes and 
develop a niche sector and 3) development of the local industry are critical for the success of 
regional Biotechnology clusters. The next section focuses on one of the critical enablers of 
growth in the Biotechnology industry, i.e national governments involvement.  
2.3 Biotechnology industry in different markets 
 
While the Biotechnology industry tends to develop as a function of addressing industry needs or 
social challenges, the early stages of developing the industry requires public support and 
coordination (Prevezer, 2001, Papadimitriou and Mourdoukoutas, 2002; Ahn et al, 2012). The 
involved of government in this industry has been reported for various countries and for those 
where the involved was strategic and focused, the outcomes were positive. 
2.3.1  The US’s government involvement in the Biotechnology Industry 
The US government played a significant role that led to the USA being a market leader in this 
sector. The government supported the industry through funding basic science research though 
institutions such as the NIH, relaxing the government control over the commercial use of the 
outcomes of publicly funded research through the Bayh-Dole Act of 1980 and the provision of 
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strong IP protection. Through the Orphan Drug Act of 1983, biopharmaceutical companies were 
encouraged to invest and develop drugs for rare diseases, by providing generous tax incentives 
and market exclusivity for 7 years from the time that the drug was approved for commercial sale 
by the Food and Drug Administration (Lazonick and Tulum, 2011). To bridge the financing gap, 
the US government implemented five policy measures which led to a growth in the venture 
capital industry. These included 1) creation of small business centers to assist start-ups with the 
business plan development, 2) the revision of the Investment Company Act of 1940, allowing 
the creation of limited partnerships that paid fund managers by performance, 3) revision of the 
Employee Retirement Income Security that allowed pension fund managers to invest small 
portion of the their fund in start-ups and venture capital funds, 4) reduction in the capital gains 
tax from 49.5% to 28% which made high risk/high return investments more attractive, 5) 
introduction of the NASDAQ Small Cap market that made equity markets more accessible to 
smaller firms and allowed recycling of funds (Papadimitriou and Mourdoukoutas, 2002). 
2.3.2  European (UK and Switzerland) government involvement in the 
Biotechnology Industry 
 
The biotechnology industry in Europe is not as advanced as it in in the US and countries within 
the European Union vary with regards to the market and sector maturity, with the UK, 
Switzerland and France having the largest market capitalization of the companies in the sector 
(Ernst & Young 2013 Biotechnology Industry report). In general, the governments in these 
countries play an active investor role in ensuring growth of the industry on a national level 
through policies that aim to stimulate growth of the sector. Furthermore, they set up seed capital 
instruments to provide early stage start-up financing and actively invest funds in venture capital 
firms to increase the pool of funds available. On a regional level, they focus on shaping local 
interactions, providing infrastructure and support services through incubators, science parks and 
regional funding and creating niche areas of specialisation in each of the regions (Autant-
Bernard, 2006). A critical aspect that was also driven by government owned universities was the 
openness to partner with large firms, positioning themselves as their R&D centers. These 
relationships become a stimulant of university spin-offs and created an immediate market for the 
spin-off companies (Papadimitriou and Mourdoukoutas, 2002, Autant-Bernard, 2006). 
Furthermore, instruments such as the Welcome Trust, European Frame Work Program and 
Biotechnology clusters are also very common means through which the governments of these 
countries stimulated the growth of the sector (Papadimitriou and Mourdoukoutas, 2002).  
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2.3.3  Israeli’s government involvement in the Biotechnology Industry 
The Israeli biotechnology industry is young, rapidly growing and plays an important role in the 
global industry. The broader Life Sciences industry represents about 50% of Israeli’s civilian 
research activities and has the highest concentration of scientist per capita (Zeevi and Alon, 
2012). The Israeli government played catalysts role in the development of the Biotechnology 
industry. Its involvement started in the 1980’s and the early 1990’s when the government 
attempted to leverage off its military technology poweress and a mass influx of Soviet 
immigrants scientists that boosted its scientific research capabilities. The government’s efforts 
focused on bridging the early-start-up financing gap, providing financial assistance to start-ups 
and to joint ventures between entrepreneurs and established companies. They government also 
set up a Yozma group of funds, a $100 million investment company which was privately 
managed, that allocated funds to high technology companies in two ways. 1) by taking direct 
investment position in 15 start-ups which included one of Israel’s signature Biotechnology 
company, Bioscience Inc. at $1 million. 2) setting up drop-down funds together with strategic 
partners. In addition to providing equity financing, the Yozma Group management team 
participated on the board of directors of its start-up portfolio of companies, monitored their 
performance, and assisted them with personnel recruitment, business plan development, 
business networking and access to international partnerships. Since 1993, close to 120 Israeli 
companies have managed to list their shares in various American exchanges, raising $6 billion 
in total. In 1999 alone, 12 Israeli companies listed their shares on the NASDAQ raising close to 
$2 billion (Papadimitriou and Mourdoukoutas, 2002). The Israeli government has benefited from 
its investment across various technology sectors. In the Biotechnology sector for example, the 
government cashed out its investment in Bioscience Inc. which was sold to Johnson & Johnson 
for $340 million. 
2.3.4  The Brazilian’s government involvement in the Biotechnology 
Industry 
Brazil is well known for its research and investment in industrial biotechnology, particularly in 
sector of cellulosic sugars for the production of biofuels and agribusiness. At present, Brazil has 
143 biotechnology companies, with 75% of these being located in the south eastern states of 
Sao Paulo, Minas Gerais and Rio de Janeiro (Resende, 2012), consistent with the regional 
approach that most biotechnology firms assume. Overall, the Brazilian biotechnology industry is 
very young with companies in biofuels and the agribusiness being the oldest. Health 
biotechnology companies have only The Brazilian government has played in strong catalytic 
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role in the development of the Biotechnology industry by putting in place mechanisms such as 
creation of financing programs, development of specific laws that govern biodiversity and 
intellectual property. The Government of Brazil has increased significantly its support of 
researchers in the biotechnology sector over the past few years. The number of project grants 
provided to help researchers transform their discoveries into businesses is also increasing every 
year and so is the amount of money invested by the government to help finance start-up and 
small companies (Rezaie et al., 2012). The Brazilian Gross Domestic Expenditure on Research 
and Development is significantly higher than that of South African and India as discussed in 
detail in section 1.2.  
The last five years have been marked by the implementation of industrial policies favoring 
companies in the health and life science areas, with the approval of non-reimbursable funds, 
establishment of government programs to support internationalization of the sector and 
progress in university-industry interaction mechanisms (Resende, 2012). The reimbursable 
funds include public funds from institutions such as the National Social and Economic 
Development Bank (a federal public company) for long-term financing for investment in all 
sectors of the economy. Another vehicle is through the Brazilian Innovation Agency (FINEP), a 
public company linked to the ministry of Science, Technology and Innovation. FINEP provides 
both reimbursable and non-reimbursable funds for companies in the Science, Technology and 
Innovation fields, thus being a critical catalyst in inducing innovative activities. The government 
has also set up publically owned venture capital funds through institutions such as BNDESPar 
and CRIATEC which provide seed capital and also acquire an equity interest in the companies 
they fund. There has also been an increase in Brazilian tax incentives (Resende, 2012). Unlike 
the Indian Biotechnology Industry, the Brazilian government maintains a prominent role in 
commercial entities, favoring a more public-private partnership model (Rezaie et al., 2012). 
2.3.5  India’s government involvement in the Biotechnology Industry 
In India the government played a critical role when establishing the department of Biotechnology 
in 1986 that among various initiatives has also focused on infrastructural facilities and promoting 
and supporting public-private partnerships that invest in commercialization of R&D. The India 
Department of Biotechnology has also used social contracts with small companies and non-
profit organizations that focus on public good technologies such as healthcare, bioenergy and 
agriculture to link innovative product development to developed products to create maximum 
social impact. This type of social innovation work has been conducted in partnership with 
institutions such as the Gates Foundation and the Wellcome Trust. Another of its impactful 
15 
 
initiatives is putting in place incentives for commercialization of IP produced by publically funded 
research projects (Ahn et al., 2012).  
The government of India, has taken avenues to create funding streams for innovative 
biotechnology companies, particularly those in the early stages of commercialization. In 2010 it 
formed a government backed venture capital fund to support drug discovery and invest in 
research infrastructure. The government Biotechnology Industry Research Assistance Council 
also offers Biotechnology Ignition grants geared towards early-stage ventures, offering grants 
ranging from $100, 000 - $1.6 million. Furthermore, the Association of Biotechnology Led 
Enterprises (ABLE) established an angel investment fund, where wealthy individuals with 
knowledge in the sector or expatriates would commit funding of $1-2 million each (Association 
of Biotechnology Led Enterprises, 2012 report). The global competitiveness of India’s private 
industry in both vaccine and therapeutics is mainly as result of the relatively limited involvement 
of government once the technologies are commercialized. Thus government funds the initial 
development and the companies become completely privatized as the mature. (Rezaie et al., 
2012) 
These examples illustrate that the success of this industry is heavily depended on 
Biotechnology firms leveraging on the various government interventions and developing 
innovating products that address a myriad of health, agriculture, Industry and the environmental 
challenges across the world. Furthermore, access to finance it’s a critical determinant of the 
success or failure of these firms. 
A study by Cetindamar and Laage-Hellman (2003) examined the dynamics of growth in the 
Biotechnology sector in Ohio and Sweden, regions that were similar from a population size 
perspective, GDP per capita and were regions that posed a need to restructure their heavy 
industry reliant economies to high technology industries. Similar to South Africa which has in it 
2014 national Bioeconomy strategy, identified the Biotechnology sector to be one of the major 
drivers of economic growth in the technology sector, these two regions had in 2003 identified 
the Biotechnology sector to be a key driver of techno-economic development. Cetindamar and 
Laage-Hellman’s 2003 comparative study revealed that resources allocated to technological 
competence development in terms of availability of various types of funding streams and an 
enabling environment that supports start-up companies are among the critical factors. This 
research also indicated that a majority of biotechnology firms in these two regions are university 
spin-offs. An interesting finding was that Biotechnology firms in Sweden received less 
government funding when compared to those in the US, testament to the USA’s support for pre-
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commercialization research and market driven innovations. Furthermore, start-up companies in 
Ohio had easier access to venture capital finance compared to those in Sweden where the 
venture capital sector is not at the same size as that in the US. This study clearly indicates and 
supports the superiority of the US Biotechnology sector versus other countries. These empirical 
studies, all aim to identify factors that would significantly grow the Biotechnology sector in the 
respective countries analyzed. The research presented in this thesis aims to determine that in 
the myriad of factors that could lead to the growth of the industry, what role do financing models 
play in stimulating growth of the industry and thus the next section addresses the funding 
mechanisms of Biotechnology start-up companies. 
2.4  Funding mechanisms for Biotechnology SME’s 
A critical factor for the establishment of SME’s irrespective of the sector is access to funding 
across the various stages of the business cycle. Potential funding alternatives including, 
government grants, angel investors, development banks, private equity and initial public offering 
exist. The specific funding nuances experienced in the Biotechnology sector are discussed in 
section 2.4.1. 
2.4.1 Financing of biotechnology companies 
 
For most young biotechnology companies, financing the expensive development milestones 
depends on the availability of capital from venture capital investors and the stock markets. Thus, 
the development of this industry is substantially influenced by having an established financing 
environment (Patzelt and Audretsch, 2008). For many start-up companies, who cannot access 
any public equity financial markets, the private equity market tends to be the best option. Capital 
for private equity investments can be raised from retail and institutional investors, and at times 
private investors and can be used to fund new technologies, expand working capital within an 
owned company, make acquisitions, or to strengthen a balance sheet (Masum and Singer, 
2011). The majority of private equity consists of institutional investors and accredited investors 
who can commit large sums of money for long periods of time. Private equity investments often 
demand long holding periods of generally 5-10 years to allow for a turnaround of a distressed 
company or a liquidity event such as an Initial Public Offering (IPO) or sale to a public company 
(Portmann and Mlambo, 2013).  
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The private equity sector has distinct subdivisions such as venture capital and Buy-out funds, 
and can have industry or field specialization. In the Biotechnology sector, the growth of the 
Venture Capital funds has played a significant role in driving growth. Venture Capital funds 
generally invest in the early stages of business cycle of an SME (i.e start-up, seed or expansion 
funding), where growth prospects are significantly high and the funds tend to be focused on 
technology firms. Buy-out funds invest in larger mature enterprises that show some stability in 
revenues, where the intention of a Buy-out fund would be to radically transform the firm or 
significantly improve sales and earnings (Smolarski et al., 2011). Private equity investments, 
particularly venture capital funds, furthermore entail having the PE firm’s management team 
being part of the investee company management team, an aspect which is critical for this 
sector, where the innovators tend to have very little business management knowledge. 
Private equity penetration in developing markets remains relatively low. In 2011, private equity 
investment as a share of GDP was ~1% for the US. Even in larger emerging markets, that 
promise large growth like China and India (IMF report, 2011), penetration remained significantly 
lower (Wilton and Laird, 2013). Some of the reasons provided by Wilton and Laird, 2013, are 
high perception of risk about these markets; less experienced fund managers and information 
asymmetry. To address these, it is important that systematic market understanding, strong local 
presence and understanding the dynamics of the emerging markets are in place (Wilton and 
Laird, 2013). As with all private equity fund investment, effective due diligence is critical. In 
emerging markets, the diligence will need to be highly focused on the capabilities and skill set of 
the management team, relative to the market in which it operates, as opposed to the primary 
focus on prior success as applied in most developed market private equity where the data is 
available.  
One of the critical success factor in the US that enabled the growth the Biotechnology sector 
was the availability of a pool of scientifically aware venture capitalist that were eager to back 
commercially viable scientific ideas/products, linking scientists with entrepreneurs and 
individuals with strong managerial skills. (Prevezer, 2001). Furthermore, Prevezer also found 
that, the funding of the scientific R&D rather than the funding of the biotechnology industry 
directly provided the foundation for start-ups to be created. A key example of this is in the 
innovative cancer medicines, where institutions such as the NIH within that the National Cancer 
Institutes were responsible for 64% funding of R&D. This is return created an emergence of 
biotechnology companies that have positioned the USA as the market leader in development of 
innovative cancer therapeutics. The initial attitude of USA investors in the 1980/1981 was rather 
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bullish, where there was significant proportion of venture capital that was availed for this sector. 
However, investor sentiments in this sector have with time had its lows and highs (Schweizer 
and Knyphausen-Ausfsess, 2008) 
A second critical factor that enabled the growth and vibrancy of the US biotechnology industry 
was the role of the stock market for new companies and the IPO market. IPOs are often issued 
by smaller, younger companies seeking the capital to expand their enterprises. In an IPO, the 
issuer obtains the assistance of an underwriting firm (usually a bank), which helps it determine 
what type of security to issue (common or preferred), the best offering price and the time to 
bring it to market (Ragupathy, 2011). The amount of funding raised varies depending of the IPO 
pricing, associated costs and the market value of the stock. This model of access public 
financing is very prominent in the biotechnology sector. 
When compared to other economies the US IPO market, was and is still more open to 
biotechnology start-ups. The ability to make an IPO and open up the raising of capital to the 
wider public also gave venture capitalist and the founders of companies an exit route (Prevezer, 
2001). An example of a successful IPO (which was valued at $300 million), was that of 
Genentech in the 1980’s where it managed to raise a substantial amount of funds. The IPO 
opened at $35 price per share and reached as high as $88 price per share. In 2009 it was fully 
acquired by the Swiss-based healthcare company, Roche, for $47 billion. Roche had held a 
majority stake in the company since 1990, attesting to the heavy reliance of the biotechnology 
start-up companies the larger established firms as their customer. 
In South Africa, where the government is still the largest funder in this industry, government 
grant play a significant role. A government grant is an award of funding from government or its 
funding agencies that does not need to be repaid (i.e not obligation for the enterprise to pay 
interest or the principal), does not accrue interest, and has strict guidelines for application that 
should meet governments’ mandate (Fraser, 2004; Kongolo, 2010). These grants are 
administered and managed by agencies that governments in countries such as the UK and 
South Africa would have established for the purpose of supporting small enterprises. In South 
Africa, the funds available from these agencies are aligned to the enterprise meeting key 
deliverables such as broad-based black economic empowerment (BBBEE), job creation and 
developing the economy of the country (Kongolo, 2010; Lukács, 2005, Falken et al., 2001). As 
mentioned below, this specific model of providing government grants will be assessed in the 
thesis and the appropriateness or ipmact thereof be evaluated. 
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Furthermore, because of the characteristics (small, costly, negative cash flows, long time to 
develop a product etc.) of biotech companies, their financing is challenging. Most biotechnology 
companies also explore the avenue of seeing financing through partnering with larger firms such 
a pharmaceutical companies. This has recently been the major business and funding strategy 
for Biotechnology firms, where large pharmaceutical companies have cut their R&D budgets, 
experiencing patent cliffs and are seeking for close to commercial innovations to include into 
their pipeline (Bloomberg Business week: Global Fiscal 2012 sales for drugs). Secondly, the 
reduction in funding that is made available by pharmaceutical companies for Biotechnology 
ventures has significantly limited the pool of funds available over the recent years. These 
scenarios have led to a high incidence of Biotechnology firms with an exit strategy being to 
partner through either, mergers and acquisition (M&A), joint ventures (JV’s), licensing or selling 
their companies to the larger established companies (Schweizer and Knyphausen-Aufsess, 
2001). A study by Patzelt and Audretsch (2008) also indicated that in the German Biotechnology 
sector, during periods of low VC investments and closed stock markets, biotechnology start-ups 
entered into strategic alliances and M&A’s as a means of surviving during these times as well as 
exit strategies. Biotech M&A activity is currently at a four-year high as large pharmaceuticals are 
facing major patent cliffs. So far in 2012, the volume of biotech M&A’s has exceeded $25 billion, 
compared to roughly $10 billion in the same period for 2011. Pharmaceutical companies’ 
patents have expired, and as a result they have holes in their revenue line they are trying to fill. 
The other benefit for large companies is the expansion their pipeline that these M&S or JV’s 
provide (Mergers and acquisition in the biotech industry currently at a four-year high. Marketwire 
August 24, 2012). 
 
In the paper by Schiff and Murry (2004), the importance of alternative financing mechanisms for 
Biotechnology companies, particularly those in the biopharmaceuticals sector was detailed. 
What has led to this exploration of funding models is that most biopharmaceutical companies 
(approximately 80%) do not have a commercial product by the time of IPO, however are mainly 
R&D entities or earn royalties based on products commercialized by other partners (Pisano, 
2006). In their work, Schiff and Murry (2004) underline the importance of Special Purpose 
Entities (SPE’s), where since the 1980’s, the R&D investments in the US have been made 
through these SPE’s in which inventors and investors each have equity stake in a new joint 
venture founded in the form of an R&D limited partnership or Special Purpose Corporation 
(SPC). Through this strategy, the technology developer gives up certain IP rights by transferring 
part of the technology to the new SPE and generating the finance for further R&D. Special 
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Purpose Accelerated Research Corporation (SPARC) and Stock and Warrant Off-balance-
Sheet Research Development (SWORD) are brand names of SPE’s that have enabled 
companies such as Amgen, Genentech, Genzyme and Biogen to finance the initial phase of 
R&D that ultimately generated blockbusters (Schiff and Murray, 2004). Another example is 
Affymax a venture backed biopharmaceuticals company which was created in 2001 and 
managed to raise $92 million via IPO in 2006, 4 years before it had a drug in the market. What 
also allowed this was Affymax R&D partnership worth $11.7 million with a Japan-based 
pharmaceuticals company, Takeda. Takeda had exclusive rights to market the drug outside of 
the US. As part of the R&D partnership, Takeda purchased 2.1 million shares in Affymax at $10 
million, which at the time of the IPO the shares that Takeda owned were worth $63 million 
(Lazonick and Tulum, 2011).  
 
Although these examples are provided as a mean to support the growth of the industry, the 
financial performance of the industry had high and lows, with specific lows being encountered in 
the period 2001-2002 and in 2008. Despite the fact that most companies faced challenging 
funding environment post 2008, capital raised increased raised from 2009 -2011 fueled mainly 
by large debt offerings by the industry’s largest firms as detailed in the subsequent section. 
 
In South Africa this sector has grown over the years, however the success of the sector in 
markets such as the USA has not been replicated in South Africa due to factors such as 
investment criteria applied, concerns about the economic growth prospects and the risk 
aversion of the investors (Portman and Mlambo, 2013). It has also been reported that that 
investors in South Africa tend to invest in sectors that are less risky and they have superior 
knowledge of (SACVA-KPMG private equity survey 2013). The situation in South Africa is that 
very little in known about the impact and growth opportunities in the Biotechnology sector, such 
that private equity investment in this sector is still limited to a handful of companies (Masum and 
Singer , 2011). 
2.5 Funding performance of Biotechnology markets 
Since 2009, biotechnology fund raising amounts have in Northern American and Europe been 
mainly driven by debt financing by mature Biotechnology companies (i.e revenues higher than 
$500 million) with amounts increasing from $15 billion in 2008 to $33 billion in 2011. Of this 
amount, the capital available for smaller companies has very much remained the same 
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averaging about $15.2 billion between 2009 and 2012 (Ernst & Young 2013 Biotechnology 
Industry report).The US raised $23.3 billion in 2012, the second highest total since 2002, with 
50% of these funds being debt financing, 28% follow-on funding, 17% being venture financing, 
and 3% being IPOs. Of the total venture capital available for technology firms in the USA, the 
Biotechnology sector accounted for 12% of these funds. As previously discussed, these funds 
tend to be concentrated in specific regional centers, where the San Francisco Bay area received 
the most, followed by New England, and San Diego as the major centers of financial 
concentration.  
The European biotechnology industry in the same period reported $4.2 billion funds raised, with 
similar split as in the US between debt financing, follow-on, venture capital and IPOs. Europe, 
unlike the UK has suffered from the fact that the traditional venture financing model has 
collapsed due to specific strains such as long timelines, high levels of perceived risk, 
management teams that often lack the proven track record and the non-existent IPO market for 
Biotechnology firms (as seen by limited capital raised through IPOs which was at $40 million in 
2012 compared to the $765 million raised in the same year in the US). The leading European 
countries that contribute to the highest capital raised are the UK, Germany, Switzerland, 
Sweden, and France (Ernst & Young 2013 Biotechnology Industry report).  
In 2012 the Biotechnology sector, capital raised in IPOS’s fell slightly from $857 million to $805 
million, while funds raised in follow-on funding increased. Overall the US IPO market for 
Biotechnology firms remains very much tepid and almost non-existent in Europe. The rising 
stock market in the US has helped the IPO aftermarket performance over the last three years, 
but very few generalist investors are interested in Biotechnology IPOs. Instead most IPO deals 
are bought by concentrated group of specialist investors who can largely dictate timing and 
valuation (Ernst & Young 2013 Biotechnology Industry report). While the IPO market is a 
domain for specialist –type investors, the US follow-on public offering attracted more diverse set 
of investors mainly due the overall strong stock market performance of the sector. It is clear 
from the literature presented in this section that there are key challenges faced not only by small 
Biotechnology firms, but by SME’s in general. Thus the next section aims to discuss these 
challenges in more detail. 
2.5.1  Funding challenges faced by start-ups and small businesses 
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Emerging countries are characterized by small domestics markets, inadequate infrastructure, 
high transportation costs, shortage of capital and foreign exchange, weak currency, lack of 
access to technology and foreign markets and surplus of low quality skilled labour are among a 
myriad of factors that SMEs in these markets need to engage with and find ways to overcome 
(Ogbo, 2012). These challenges also encompass those that are not unique to emerging 
markets, but generic across the SME sector and are further amplied by sector specific 
challenges as discussed for the Biotechnology sector. These include, lack of appropriate 
financing instruments, lack of management and entrepreneurial skills, limited access to large 
markets due to logistics constraints and lastly, constraining regulatory environment (Abor and 
Quartey, 2010).  
As discussed biotechnology firms, similar to various SME’s are not immune to funding 
challenges. Typically, these firms experience challenges in the late stage R&D phase, where 
research or government grants are no longer the relevant instrument for financing and the late 
stage business development phase where they need to grow and they require late stage equity 
capital. These gaps have led to failure of many biotechnology start-ups, prompting many 
governments to intervene, whether in a passive manner (i.e provide funds, regulations and 
mechanism to generate returns), catalyst role (i.e provide direct start-up financing and creating 
drop-down funds that provided later stage financing and management expertise) or an active 
investor (i.e invest government funds in the venture capital industry, setting up and 
administering seed capital) as was reported by Papadimitriou and Mourdoukoutas, 2002. 
Furthermore, in seeking finance for start-ups in the Biotechnology sector, their IP is an important 
factor, which can be and in more cases than not is applied to valuate a company when 
investment decisions are made. This aspect is critical when unlocking the funding and financial 
performance of firms in this industry. Thus, section 2.6 focuses on unpacking the valuation 
models and particularly using IP as an intangible asset that a firm’s value is based on. The lack 
of access to sufficient and appropriate financial resources to meet operational and investment 
needs remains a major challenge that limits the impact SMEs could have on the economy. 
2.5.2  Financial performance of the biotechnology Industry 
A study by Pisano in 2006, combined data of 263 publicly held US biotechnology firms to 
generate totals for revenues and operating income for companies from,1975-2004. In 2004 
combined revenues were $38.5 billion and operating income was at $2.5 billion. When the 
financials of the then largest firm, Amgen were omitted, the revenue was $25.2 with operating 
losses of $2.1 billion. In the same period, venture capital invested $38 billion in US 
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Biotechnology firms. This data indicated that this sector was not a highly profitable sector 
(Pisano, 2006). These results are further captured over a number of years in the Ernst & Young 
Biotechnology Reports. This aggregate unprofitability of the industry began to change in the 
2000’s when high double digit revenue growth and the overall maturity of the industry began to 
move the industry closer to profitability (Ernst &Young 2013 Biotechnology report). What has 
also emerged over time as discussed in section 2.2, is that due to the needs of this industry 
development, i.e intense interactions among scientists, entrepreneurs and funders, cluster that 
provide this conducive environment tend to have the highest concentration of biotechnology 
firms and attracting investment. In the US for example, of the $27.6 billion in venture capital 
invested in biopharmaceuticals firms during 2001-2006, 24.8% was in the San Francisco, CA 
area, 17.6% in the Boston, MA, 12.8% in the San Diego, CA area and 12.4% in the New York 
City/ New Jersey area (Lazonick et al., 2007). 
In the US, and other development markets, the existence of a speculative stock market enables 
investors to generate some return on their investment without having to wait for a biotechnology 
firm to have a commercial product in the market. Speculative stocks are prevalent in industries 
such Biotechnology, Mining and Energy. In their paper, Lazonick and Tulum confirm the 
speculative nature of biotechnology investments by showing the relation between the NASDAQ 
Composite Index and the value of venture backed biopharmaceutical IPOs. This work illustrated 
that between the period of 1979-2009 stock market speculation was a critical inducer of venture 
financing of the biopharmaceutical industry (Lazonick and Tulum, 2011). As mentioned in 
section 2.3.1, Takeda managed to gain a return on its shareholding in Affymx because of public 
investors who were willing to speculate in the shares of a company that still had about 4 years 
to commercialize their product. The availability of stock market investors, who are looking to 
make speculative gains on stocks, attracts both venture capital and big pharmaceutical 
companies to invest in this sector, where movement of stock prices is based on R&D advances 
and outcomes of clinical trials. The gains and losses in this regard are highly depended on 
information symmetry, where well informed investors will buy or sell at the time that R&D and 
clinical data are looking positive and they know when to sell their stocks. One of the critical 
measures of financial performance in this industry that is so heavily reliant of innovation is the 
R&D spending. After the 2008 financial crisis, this measure fell with R&D spending in 2012 by 
public companies in the four established biotechnology sectors (USA, Europe, Canada and 
Australia) growing by only 5% compared to the 9% growth rate in 2011.  
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2.5.2.1 The Unites States Biotechnology Industry financial performance 
The revenues of the US publicly traded biotechnology firms grew by 8% in 2012, compared to 
the 12% growth seen in 2011. Given the skewed nature of Biotechnology industry revenues, this 
change was driven by events at a few companies. However there are still trends that points 
towards this decline, which include an increasing competitive market place (as seen by 
development new generation cheaper products) and to some extent drug reimbursement 
challenges from payers and providers. The US Biotechnology industry R&D expenditures 
increased by 7% in 2012 compared to the 9% in 2011, with about 41% of the Biotechnology 
firms having significantly cut their R&D spend. However, the industry’s net income increases by 
34%, largely reversing the decline in net income that occurred in 2011. The performance (i.e 
revenue growth and R&D expenditure) of US commercial leading firms (i.e those with revenues 
above $500 million) was significantly better than that of the smaller companies. A significant gap 
between commercial leaders and smaller companies was in their R&D spending, where 
commercial leaders increased expenditure by 18% while smaller companies cut spending by 
5%. Even through the US stock market had been on a steady growth since 2012, reaching new 
high since the 2008 crisis, the Biotechnology stocks managed to perform even better with the 
US Biotechnology industry outperforming the Dow, NASDAQ and Russell 3000. Companies of 
all sizes benefited from this trend. (Ernst & Young 2013 Biotechnology report). 
2.5.2.2 The European Biotechnology Industry financial performance 
Revenues of European publicly traded Biotech companies grew by 8% in 2012, similar to the 
growth experienced in the US. R&D expenditures decreased by 1% indicating that most 
European Biotechnology firms are still cost-cutting. This is also likely a reflection of differences 
in the European market where access to capital is more challenging and the also the economic 
challenges that the region was experiencing at the time. However, capital raised by European 
public companies reached high level in 2012 mainly due to the large debt financing by a few 
companies that were able to advantage of the low interest rates. Similar to the US market, the 
performance of Biotechnology Commercial leaders different to that of smaller companies, where 
commercial leaders exhibited a 6% growth in 2012 and smaller companies reported a 16% 
growth in revenues in the same period. This was however reversed when it came to R&D 
expenditure, where commercial leaders increased by 3% and smaller companies reduced by 
5%. Unlike the US market, European Biotechnology stocks performed at the same level at other 
overall market (Ernst & Young 2013 Biotechnology report). 
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2.5.2.3 The Israeli Biotechnology Industry financial performance 
Of the 24 incubators that Israel has, 12 are solely focused on supporting and investing in Life 
science companies (In this context, life science includes medical devices, health services, 
medical IT, agriculture biotechnology, pharmaceuticals and health biotechnology). Of the 920 
life science companies in Israel, there are 175 active agriculture and health biotechnology 
companies. Industry partnership with companies such as Merck Serono, GE Health care and 
Johnson & Johnson play a significant role in providing strategic partnership for the companies. 
The oldest biotechnology company Teva Pharmaceuticals was founded in 1901, and in the last 
decade, about 40-80 life science companies were established every year and it peaked in the 
period between 2006-2010. 39% of all the life science companies are at revenue generation 
stage, with the rest being in pre-clinical, clinical or seed stage. The majority of companies 
employ 1-10 employees, but with the revenue generating companies employing between 20-50 
employees (Zeevi and Alon, 2012). According to the IVC-KPMG high tech 2012 survey, out of 
the $1.9 billion raised by Israeli hi-tech companies, 26% was raised by life science companies. 
In 2012, 135 life science companies raised approximately $500 million compared to the $350 
million raised by 114 companies in 2010 (Zeevi and Alon, 2012).  
On the Tel Avivi Stock Exchange (TASE), life science companies represent the largest group of 
listing, with about 58 companies, with seven of these being dually listed on foreign markets such 
as the NASDAQ. The limited or lack of liquidity in the Israeli stock market is a major challenge 
for these companies. The TASE continues to play a significant role in providing these 
enterprises with a platform to raise public funds and to move from TASE to NASDAQ. Between 
2005 and 2012, 23 Israeli life science companies were acquired at a value equal to or less than 
$40 million each providing an aggregate of value of acquisitions to $3.8 billion. 2012 has to date 
been the best performing year for acquisition in life sciences, which totaled about $1.3 billion, an 
amount which was 2.5 times more than the value of the 2011 acquisitions. Zeevi and Alon, 
2012, further report that in general of all exits that occurred since 2003, the average amount that 
was invested (either by government, VC or seed funds) was $32.1 million with an average exit 
return of $151.4 and the average multiple of 12. The average time for exit, was similar for those 
in other established markets such as US at approximately eight (8) years. 
2.5.2.4 The Brazilian Biotechnology Industry financial performance 
The biotechnology sector in Brazil continues to experience significant expansion and presents 
US companies (the largest biotechnology market) significant export opportunities. Of the 143 
biotechnology companies in Brazil 29% generate an annual gross revenue of over $600 000 
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and 54% generate up to $600 000 and 17% are pre-revenue according to the report by 
Resende in 2012. Similar to the South African scenario, most of these biotechnology companies 
are highly depended on fearing imports, especially reagents and equipment for production and 
development, such that the government policies have focused heavily on import substitution and 
lowering the cost of production to reduce the eventual price of the products (Rezaie et al., 
2012). Furthermore, these companies tend to either in-license technologies and produce locally, 
assume a third party role through distribution rights, and a small proportion develops their own 
IP which they then out-license.  
Unlike many of the Biotechnology developing market, Brazil has a number of large corporates in 
the sectors such as the cosmetics where they leverage on their biodiversity and chemical 
industry where production of fuels and biofuels are main economic drivers. Private companies in 
these industries invest a significant portion of their revenues (3-10%) in innovation applying 
various models such as co-development, licensing and technology transfer (Resende, 2012). As 
mentioned in 2.3.4 the main government led venture capital fund CRIATEC provides seed 
capital for most start-ups in the country. In August 2011, CRIATEC had invested in 28 
companies. A privately held Burril Brasil I fund, a subsidiary of the US Burril & Company also 
invests in Biotechnologies in Brazil. INOVA Biotecnologica is another venture capital firm that 
focuses on animal health biotechnology products and it invested $120 million in 2012. 
2.5.2.5 The Indian Biotechnology Industry financial performance 
Another case that is relevant to the South African context is the Indian Biotechnology Industry. 
According to Ahn et al., 2012, the Indian Biotechnology industry, contributed 8% of the Asia-
Pacific region Biotechnology Industry, a region that represents 26.4% of the global 
Biotechnology Industry. Thus, India represents 2% of the global Biotechnology Industry, with its 
biopharmaceutical sector being the world leaders in vaccine production, and the generics 
manufacturing sector being one of the largest in the world (Ahn et al., 2012). As the cost of 
bringing new molecules to the market increases, the global biopharmaceutical industry is 
exploring ways to improve efficiencies, making the bioservices sector in India a great 
opportunity. India’s low cost of services, skilled labour and a large population size, make it 
attractive for global biopharmaceutical companies looking to conduct low cost drug development 
R&D. 
The sector employs over 20 000 people and is rapidly expanding with 400 companies as 
mentioned in section 1.2. The agriculture Biotechnology sector is the fastest growing 
Biotechnology sector exhibiting a growth rate of 37% between 2009 and 2012. A key driver of 
27 
 
growth of the sector in India is the immense interest in the export market, including the US, 
Europe and other developing countries. India’s foreign sales have increased by 21% annually 
from 1996-2005, and the biotechnology sector as a whole, receives about 56% of its revenues 
from exports (Rezaie et al., 2012). India’s Biotechnology sector for the year ending March 2013 
reached sales of $4.3 billion according to the annual Biospectrum ABLE survey. Over the past 
decade, the industry has grown at a compounded annual average rate of approximately 20%, 
however growth has slowed in the recent years. Biocon, and Indian biopharmaceutical company 
which ranks first in India in terms of revenue, was placed among the top 20 biotechnology firms 
globally in 2010 (Ahn et al., 2012). Biocon today has more than 7 100 employees and $344.5 
million in revenue which represents 8% of all the revenue generated by the Biotechnology 
Industry in the 2013. Of the 400 companies India has, 20 of these generate almost half of the 
industry’s total revenue in fiscal year of 2013. Thus, with India having BERD of 0.88% similar to 
that of South Africa at 0.76%, comparable socio-economic challenges and being an emerging 
market like South Africa, the question then remains, that what is lacking in South Africa that 
limits it from having companies such as Biocon and contributing significantly to the global 
biotechnology industry. Access to capital for early-stage biotech companies in India continues to 
hamper development. The typical characteristics of the sector, compounded by India’s lack of 
tight and predictable regulatory and legal systems make it difficult for this sector to attract 
private investments. In 2012, the sector raised $24 million from private funds and none the 
previous year (Indian Brand Equity Foundation, 2013). As mentioned in section 2.3.1, early 
stage funding is almost always led by India’s government.  
 
A factor that has been reported to hamper growth of the Biotechnology industry in emerging 
markets such as Indian and Brazil addressed above is limited financial exits for venture capital 
investors. Although the stock market in some of these countries are advanced, e.g. South Africa 
and China, the appetite of the public market for biotechnology-based companies is still low, due 
to the limited success and the high risk of the industry (Rezaie et al.,2012).  
2.6  Valuation of biotech companies 
An important issue relating to biotech companies is how they are valued. Valuing these 
companies by discounting its free cash flow does not help much because most of these 
companies would have negative cash flows. However an important intangible asset that 
biotechnology firms hold is intellectual property (IP) in the form of patents. Intellectual property 
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rights play a very important role in the biotechnology sector. Depending on the sector, other 
forms of IP are more common, i.e trade secrets, know-how, lead times, first mover advantage 
etc. However in sectors such as pharmaceuticals, chemicals, ICT software and hardware 
patents are an important financial asset. A patent provides a temporary monopoly to the owner 
in excluding others from using it and is seen as the largest asset of any biotechnology firm. This 
short-term monopoly enables the company to sustain the economic value of technological 
knowledge and innovation to enable companies to refund their investment innovations, 
producing a high risk-return ratio. Patents are however granted for a limited period of time, 
mostly, 20 years. During this time the patent holder can transact using the patent through 
licensing options (Kulpmann, 2005). This licensing option limits the monopolistic nature of 
exploiting IP in that a licensee can utilize the IP to develop their own, commercialize it n different 
markets or improve their innovation. 
2.6.1  Intellectual property and biotech industry 
Intellectual property rights play a very important role in the biotechnology sector. Different 
countries have patent law which is a set of legal rules that govern the validity and infringement 
of patents in a wide variety of technologies (Burk and Lemley 2004). The increase in the number 
of participants in the IP landscape (producers and users) has resulted in patents being a very 
competitive business tool. Large corporations have progressively developed patent portfolios to 
strengthen their bargaining and retaliation power or to exercise patent strategies to delude 
competitors. This later is mainly observed between new and old firms and small and large firms. 
Thus patent management skills are being a critical competitive factors to any firm (Su et al., 
2012). This competitive climate, has led to an emergence of patent-based business models who 
exploit the patent values. These business models tend to create more value since they are more 
effective and efficient at application and exploitation of patents. On the hand, they may have 
detrimental effects, particularly the litigation-based business models of patent trolls (Su et al., 
2012). Thus these models may have negative effects of slowing down and hampering 
innovation and patent creation.  
 
Since the 1980’s the patenting activity and the importance of patents have increased rapidly and 
steadily. While patent values are highly skewed, patent mean value estimates have grown 
significantly (OECD, 2007). Estimates of patent values based on the European Patent Office 
(EPO) in the 1980’s were in the region of USD 20 000, whereas in those in 2005 were in the 
region of USD 400, 000. Furthermore, receipts from licensing patents increased rapidly between 
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the 1990’s and 2005 from USD 1.3 billion to USD 2.7 billion (OECD 2007). The trend has also 
moved from patent applications that secure the freedom to operate to set barriers to entry to 
those that generate additional revenues and use patents as a leveraging point in negotiations 
and gaining market leadership (Yamaguchi, 2014).  
 
Important factors that determine an innovation value to a company when considering their IP 
are, 1) whether the patent is a pioneering invention or it is an incremental improvement, 2) does 
the patent claims cover all of the revenue generating activities, 3) is the license agreement 
exclusive or non-exclusive, 4) is the innovation used in conjunction with other innovations/ 
inventions in the same product line, 5) the likelihood that the patent can withstand a challenge in 
court, 6) is the patent at an idea stage or a developed product, 7) track record of the inventor or 
inventors and lastly, 8) whether the patent can be easily overtaken by an alternative approach 
(Wilson, 2012). It is however widely accepted that one of the most important characteristics in 
terms of a patent value is whether or not a patent has been involved in a litigation or not. A 
litigated patent is more valuable than a non- litigated patent, since litigation or rather the 
outcome of an infringement proceeding impacts the patent value. Thus, if a patent protects a 
large market, has claims that have strong economic outcomes and survives litigation its value 
would appreciate (Su et al., 2012). With an increase in globalization of businesses, enterprises 
use legal based business strategies to prevent competitors from entering into the market by 
taking advantage of the legal value of patents as described above. 
 
South Africa experienced a sharp decline in patents granted at the South African Patent Office; 
however South African patents granted in countries such as the USA, Australia and Canada, 
Japan and India increased. When comparing South African patents with its BRICS counter parts 
and developed countries such as Japan, UK and USA, its world share of patents is at 0.08% 
compared to 0.29% of Brazil, 0.73% of India, 21.77% of Japan and 20.19% of USA. Thus as it 
will be discussed in chapter 2, this low contribution rate of SA’s patent in the global landscape is 
reflective, to some extent of the value and the size of the South African technology sector. Of 
this 0.08% contribution, the biotechnology sector accounts for 3% and the pharmaceuticals 
sector 4.6% (WIPO report on IP Statistics, 2011).This factor is reflective of the relatively small 
size of the biotechnology sector is South Africa compared to other emerging markets such as 
Israel, India, Brazil and Singapore. Daar et al., (2002) states that the data of the economic size 
of this sector in South Africa is not available, however a recent report by the South African 
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National Advisory Council on Innovation (NACI) on South African Science and Technology 
indicators, 2013 indicates that South Africa’s value added by knowledge and technology 
intensive industries as a percentage of GDP is competitive among the BRICS countries, 
averaging at 21% compared to developed countries such as Japan at 29.6%, UK at 38% and 
USA at 40.3%. Although this serves as some indication of the size of the high technology 
sector, this class includes sectors such as telecommunications, medical technology, 
biotechnology, pharmaceuticals, chemical engineering, environmental technology and computer 
technology. Thus, to date, no clear economic size of the Biotechnology sector is available. 
The Biotechnology sector is characterized by vast availability of intangible assets such as 
technologies, know how (in the form of patents, trade secrets etc). Furthermore, the rapid 
progress towards knowledge-driven economies has resulted in the required need to valuate 
these assets, however, there is no consensus on concrete evaluation methods and various 
methods still need to be verified (Yamaguchi, 2014). General accounting practices do not 
consider spending on intangible assets such as R&D to generate IP as investments. The 
methods that are currently applied include: 
2.6.2 IP valuation techniques 
The cost approach; which evaluates the costs necessary (past costs or costs of re-creating 
equivalent assets) necessary to create intangible assets. This method does however require 
estimation of depreciation expenses owing to the obsolescence of intangible assets. This 
method does however have the downside that it does not consider the profits actually realized 
by the assets (Reilly and Schweis, 1999). The market approach; which is a direct and objective 
method, however it requires that an active mart exists and comparable assets are traded at fair 
prices (Reilly and Schweis, 1999). The income approach; which discounts future profits created 
with intangible assets to a present value. This approach is the more qualitatively superior 
method because it reflects true benefits even though it is difficult to estimate future profits 
(Yamaguchi, 2014). Kossovysky et al. 2002 designed an evaluation method based on option 
pricing theory that values IP using the residual value after subtracting the book value of equity 
from the market value of equity. However, this method is considered an application of the 
market approach because it is based on the market value. Thus, this method requires that the 
company be listed or have similar companies being listed to determine the market value. The 
panel data method; which uses panel data, i.e longitudinal or cross- sectional time-series data, 
in the form of unobserved firm-specific effects is also applied. This model first estimates the 
production function using panel analysis and develops costs function using a duality approach 
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to derive discounted added value and costs resulting from intangible assets. Thus is 
incorporates the income approach. In this approach, the market value of equity  is more closely 
associated with both the book value of equity and the value of intangible assets than with the 
book value of the equity alone (Yamaguchi, 2014). 
 
IP provides a company with the value proposition and the ability to compete and grow in the 
market place. Another aspect that an investor looks at when financing a company based on its 
IP value would be the royalty potation for that patent.  The royalty rates differ across industries, 
with the high value industries such a Biotechnology and Pharmaceuticals with high profit 
margins would follow the 25% rule, which would yield high royalty rates. In setting royalty rates, 
a valuation method that has recently been published by Wilson, 2012, provides a retrospective 
approach. This approach uses measurable variables that indicate directly the value of the IP, 
based on the actual performance of the IP in the market, to a licensee over time. Unlike the cost 
or income –based methods descried above, this method does not require any assumptions 
about the future and thus has limited uncertainties and inaccuracies. As discussed in chapter 
one, another mechanism of valuing patents is the litigation –based precaution approach which 
looks at variables such as the number of assignee countries, number of patent references, 
number of claims and the number of foreign references to predict the probability of a patent 
infringement, and thus a determine the patent value (Su et al., 2012). 
2.7 The potential economic impact start-ups 
A successful economy has a vibrant SME sector that plays an important role in economic 
development through various ways such as creating jobs for various skilled persons, providing 
innovative solutions and diversification of sectors (Fida, 2008). With South Africa’s high 
unemployment rate, socio-economic challenges and high health burden, SME’s in the 
biotechnology sector will be critical in addressing some of these challenges. As discussed in 
section 1.2, there are a number of benefits the enterprises in this sector provide for the country 
at large. This section aims to highlight the overarching benefit of vibrant SME’s in various 
economies and how South Africa can benefit from investing in these companies, and in the 
context of this work, more specifically Biotechnology SMEs’. 
The European Commission defines small enterprises as those that employ less than ten 
employees, has an annual turnover of less than two million Euros and an annual balance sheet 
total of ten million Euros or less. On the hand, small enterprises employ between 10 and 50 
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employees with an annual turnover of less than ten million Euros and an annual balance sheet 
total of ten million Euros or less. Lastly, medium sized enterprises employ between 51-250 
employees with an annual turnover of less than fifty (50) million Euros and an annual balance 
sheet total of fifty (50) million Euros or less (European Commission, 2005). 
 
In the USA for example, SMEs are job creators that drive USA economy by providing jobs for 
half of the nation’s workforce. Small businesses represent about 99.7% of the firms creating 
more than half of the non-farm gross domestic product including 60-80% of the new jobs in the 
economy (Longley, 2006). SMEs are also the major driving force behind the China economy. 
They contribute about 59% to the National GDP by easily diversifying products, innovating and 
creating employment opportunities. In addition, these SMEs contribute 50% tax revenue, 68% 
foreign trade volume and 75% of urban employment. They are also responsible for 65%of the 
patented inventions, 80% of new products in China and are the largest stimulators of innovation 
(Cunningham, 2011). These factors are not isolated to these markets, they are observed in 
various other economies such as Japan, Korea and India where small businesses have played 
a significant role in reducing poverty, creating employment opportunities and improving the 
overall social conditions of a nation (Kongolo, 2010). In South Africa, SMEs represent a large 
proportion of business, accounting for about 91% of formal business entities and contributing 
approximately 40% of the GDP, and providing 60% of employment (DTI, 2008). In the European 
Economic area, 99% of all enterprises are SME’s with about 67% of all jobs provided by these 
companies. During the economic recession of 1988-2001, large corporates, shed more jobs, 
versus SMEs (Lukács, 2005). The UK, which has a greater presence of large corporates versus 
other European Union countries, has an SME sector that employs, 56% of the workforce, a 
number much less than the EU average, and an SME contribution of 52% of the national GDP 
(Lukács, 2005). These examples illustrate that role of SMEs is equally important in developed 
and developing countries. Most Organization for Economic Cooperation and development 
(OECD) countries have developed mechanisms that include policies and programs to promote 
entrepreneurship and support the development of the SME sector.  These include incentives 
such as tax breaks, reduced interest loans, grant funding and subsidized training to name a few 
(DTI report, 2008). However, in the developing countries, a significant proportion of SMEs 
remain in traditional activities characterized by low levels of productivity, poor quality products, 
serving small localized markets, limited technology innovation and very few companies that 
grow to become successful large corporates (Lukács, 2005), compounding the challenges. 
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SMEs tend to have advantages over large corporates in that they can adapt easier to market 
conditions; their flexibility allows them to withstand the adverse economic conditions due to 
lower capital costs and lower labour costs. Furthermore, because they tend to provide services 
and products that large corporates do not provide, more often than not, they have a competitive 
advantage. In the last decade, SME’s were the principle creators of new jobs, while on average, 
large corporates downsized and reduced employment. Opportunities for further SME growth are 
predicted for the future (Kongolo, 2010). With increased globalization providing opportunities to 
enter new markets, e-commerce, internet usage and ease of doing business in emerging 
markets, the opportunities are endless.  
 
This chapter has provided an in-depth review of the significance of the biotechnology sector, its 
role and the economic benefits that it provides. While this is critical sector for most countries as 
highlighted in chapter 1 and 2, there funding challenges that SME’s within this sector face which 
hamper the growth of the industry and these were also covered in this chapter. With the 
overarching question of this research being to determine the investment performance of funds in 
this sector as well as determining the optimal funding model, the next chapter, details the 
methods that will be applied to address this question. 
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Chapter 3: Research methodology 
3.1  Introduction 
This chapter provides the research methodology to be used in this study to determine innovative 
financing mechanisms that would lead to the growth of the sector. This chapter details how the 
data will be collected and analyzed to provide this insight. Section 3.2 provides a description of 
research methodology.   
3.2  Data collection and analysis 
 
This work is a conceptual paper where existing information from different sources is used to 
establish the performance of the South African Biotechnology Industry and other countries. This 
study evaluates and reviews the Biotechnology industry in South Africa and compares it to that 
of selected emerging markets such as Brazil, India. A review of the Biotechnology industry in 
developed markets such as the USA, Switzerland and Israel are also be included.  
 
The industry performance is evaluated in a period between 2005-2013, since in South African, 
the first Biotechnology strategy was developed and implemented from 2001, thus data on most 
companies and government efforts would be available from 2005 and any literature would be 
available from that time point. The data sources that were accessed are: 
 Global Pharmaceuticals and Biotechnology reports 
 World Economic Data sources 
 International consulting firms that focus on this sector such as PriceWaterhouseCooper 
and Ernst&Young sector specific reports 
 Institution comparison, such as TIA and IDC in South African compared to FINEP and 
CRIATEC in Brazil. 
Because this is not empirical research, the information obtained from the different sources will 
then be tabulated and analyzed.  
 
The analysis would were followed by structured expert interviews to major funders in the 
Biotechnology industry in South Africa including the IDC, TIA, the dti, DST to understand the 
funding model that they use for Biotechnology companies and identify the problems and 
advantages of the models. This will also explore what these industry funders suggest as an 
appropriate model for finding Biotechnology SME’s. The interview questions used in these 
interviews are captured in Appendix 1.  
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Chapter 4 Presentation of Results and Discussion 
4.1 Introduction  
 
The objective of this research is to provide an understanding of the investment performance of 
the biotechnology sector in South Africa (SA) compared to other emerging markets and 
developed markets. Furthermore, based on the analysis of various financing model applied in 
the respective markets, this work aims to suggest a more appropriate funding model for biotech 
sector in SA. Various industry reports were analyzed including interviews with local sector 
experts who provided either confirmatory information and also provided their insight into the 
appropriate model.  
The chapter is organized as follows: Section 4.2 provides an analysis of the biotech industry in 
developed and emerging markets, section 4.3 discusses the performance of the biotechnology 
industry in selected markets, with section 4.3.1 presenting results of the biotechnology sector 
composition in the respective markets and section 4.3.2 presenting results of the economic 
performance of the industry across different markets. Section 4.4 discusses the funding 
environment in these markets, followed by section 4.5 where elements that contribute to the 
positive financial performance of this sector are highlighted. The chapter summary concludes 
the chapter. To ensure ease of flow, the data received from the structured interviews is 
incorporated in the format indicated above to ensure ease of flow. 
4.2  Analysis of biotech industry in developed and emerging markets 
The biotech sector is highly specialized, with long development time lines, high investment 
financing needs and an environment that is conducive to business growth. As mentioned in 
section 1.2, the overlap between the biotechnology and pharmaceuticals sector is strong and 
the success and growth of the biotechnology sector is reliant of having a strong pharmaceuticals 
sector. At a global scale, the USA and Europe are the most important markets, accounting for 
half of the global biotech patents. The USA holds 46.6% of the global sales in this sector with 
the European Union at 28.5%, Japan at 8.4% and BRICS at 3.4% during the year 2012 
(EvaluatePharma, 2014). Much of the growth (29.3%) is however, expected in emerging 
markets.  
36 
 
The USA remains the market leader in the sector, with factors such as protection of IP, 
enterprise support mechanisms, quality and intensity of R&D and the availability of skilled 
workforce to support this industry being critical aspects that enable it to remain the market 
leader. Within the USA economy, the biotechnology sector continues to be one of the top 
performing sectors that also contribute to the creation of stable employment.  
Switzerland holds a strong global preeminence due to its high quality know-how embedded in 
centuries of high quality R&D and innovative cutting edge technologies. A large number of 
multinational companies have established a presence in this market, and despite Switzerland’s 
high salaries and limited natural resources, it remains an ideal country to set up a biotechnology 
firm. This is observed by the high number of foreign entrepreneurs that have established 
biotechnology companies in Switzerland.  
Brazil’s life sciences industry is increasing in the global landscape and is becoming a core of its 
economic activities. According to the Scientific American World View (2014), Brazil, is the 
second largest producer of biotech-based crops such as cotton, maize and soybeans and is a 
global leader in the production of Biofuels. The health biotech industry is also growing and is 
largely dominated by a few domestic generics manufacturers (Rezaie et al., 2008). 
India’s biotech industry has blossomed in the recent years in the liberalized IP regime (although 
not favorable to foreign investors) that allowed a number of companies to thrive in generics 
manufacturing amidst the patent cliffs experienced by many innovative multinational companies. 
Companies in Europe and the USA continue to seize the opportunities from India’s large skilled 
workforce, low R&D and manufacturing costs and the ability to serve the global growing demand 
for health and agriculture biotech products. The global recession benefited this market, as many 
USA and European companies implemented R&D and manufacturing cost-cutting programs. 
Thus, India became an ideal market to address these aspects (Ernst & Young, Global Biotech 
Report, 2010). 
The Israeli biotechnology industry is young, rapidly growing and plays an important role in the 
global industry. The broader life sciences industry represents about 50% of Israeli’s civilian 
research activities and has the highest concentration of scientist per capita. It is home to around 
1,000 life science companies. About 41% of all life sciences companies operating in Israel today 
were established during the last 10 years and over third of all sector start-ups are already 
generating revenue. 
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South Africa is a relatively small biotech market in terms of the number of biotechnology 
companies, but also in terms of the amount of funding (both government and public funding) 
and the economic impact of the sector. Since being established in 2002, with the publication of 
the National Biotechnology Strategy (2001), we deduce that the socio-economic impact lags 
behind countries such Israel and India. This is observed by having only 58 active biotechnology 
companies, of which only 12% are revenue generating. 
4.3 Performance of Biotech industry  
Table 4.1 below shows that the global biotechnology industry was strong in 2013 with the total 
global revenues increasing by 10% from 89.7 billion USD to 98.8 billion USD. This increase was 
driven mainly by 17 large companies (revenues greater than 500 million USD) in the USA who 
reported growth in revenue.. A significant improvement was observed in R&D spending that 
increased to a level close to the pre-financial crisis level indicating that most companies are 
investing in the development of new innovative products. The industry’s profits declined by 15%, 
from 5.1 billion USD in 2012 to 4.3 billion USD in 2013. This may be due to the increase in R&D 
spend observed for a number of companies. The number of public companies increased by 2% 
(from 602 to 616) mainly due to 49 IPOs in the USA and Europe combined. In absolute 
numbers, the US gained 23 new companies, while other markets lost companies. These losses 
could be due to acquisitions or delisting of the companies. The BRICS had no new companies 
that entered the market in that period. Of the 3.5 billion USD raised in IPOs, 91% was 
concentrated in the USA, with only 8 companies in Europe going public raising a total of 254 
million USD. Interestingly, three of the eight decided to list in NASDAQ rather than European 
exchanges (Ernst & Young Global Biotech Report 2014).  
Table 4.1: The global performance of the biotechnology sector (USD billion) 
Global Metrics 2012 2013 Percentage change 
Revenues 89.7 98.8 10% 
R&D costs 25.4 29.1 14% 
Net income  5.1 4.3 -15% 
Market capitalization 478.7 791.8 65% 
Public companies 602 616 2% 
38 
 
Source: Ernst & Young Global Biotech Report 2014 
Despite being one of the global leaders in biotechnology for R&D and new venture creation in 
this sector, the US balance of payments for this sector is negative with the EU being its major 
supplier of pharmaceutical and biotechnology products. The year 2012 was particularly a good 
year for the biotechnology sector in USA, with revenues growing by 8%, profits increasing by 
34% and market capitalization rose by 30% (Ernst & Young Global Biotech Report, 2013). This 
growth trend was also observed in 2013 (Ernst & Young Global Biotech Report 2014). 
According to the NASDAQ Biotechnology report Index, a 29.8% growth in 2012 was reported 
followed by an exceptional increase of 68.3% in 2013, making the biotechnology sector in the 
USA the best performing sector. In 2012, and 2013, the US biotechnology industry 
outperformed the Dow-Jones, NASDAQ and Russell 3000 (Ernst & Young Global Biotech 
Report 2014). This trend was also observed in 2005 and 2008, amidst the economic financial 
crisis (Ernst & Young Global Biotech Report 2006 and 2009). However, in 2008, the small cap 
biotechnology companies did not perform as well as mid and large cap biotechnology 
companies.  
The marked increase in growth in 2013 was mainly driven by the speculation for specific drugs 
that had successful clinical trials, the value of the addressable market increasing and a resultant 
increase in price of the product leading to a resultant increase of the companies value (Ernst & 
Young Global Biotech Report 2014). Furthermore, three strong biotech companies in the USA 
reported the biggest growth in revenues of more than 1.4 billion USD each. These peaks of high 
performance are however, always followed by dips as investors become more realistic. This 
phenomenon of speculation and peaks in this sector is not unusual, as a company can have no 
earnings one day, and the next day its value can increase due a major breakthrough in clinical 
trials or any other R&D outcomes. 
The Swiss economy is highly depended on foreign trade with a positive balance of payments. In 
2011, about 38% of Swiss exports were in the chemical, pharmaceuticals and biotechnology 
industries and they continue to grow.  Half of the growth in Q4 of 2011 was from these sectors. 
The Biotechnology industry achieved total revenues of 4.6 billion USD in 2012 compared to 4.7 
billion USD in 2011. Private capital that was raised was approximately 260 million USD, 
whereby 50% of these went to three firms. The presence of large corporates in this sector, 
provided exit strategies that enabled several Swiss biotech firms to enter into attractive M&A or 
JVs in 2012. An example of these is the Molecular Partners partnership with Allergan which 
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included an upfront payment of 62.5 million USD and milestone payments of up to 1.4 billion 
USD (Ernst and Young, Global Biotechnology Report, 2012).  
In the period between 2008-2013, Switzerland had a total of two IPOs listing, however in 2014 
alone, three Swiss companies ventured forth, with two of the three being in the biotechnology 
sector (Swiss Venture Capital Report, 2015). Unlike the biotechnology industry in the USA in 
2012 and 2013, the European biotechnology Industry performed in line with the rest of the 
markets (Ernst and Young, Global Biotechnology Report, 2014). 
 
Considering the investment made by the Indian government in the sector over the years, and 
increase in the number of alliance with multinational companies, the Indian biotechnology sector 
holds great promise. The Indian Bioeconomy grew to 4.3 billion USD at the end of 2013, from 
530 million USD in 2003. Revenue from bio-pharma exports reached 2.2 billion USD in 2013, 
accounting for 51% of total revenues of the biotech industry. The Indian biotech industry grew 
by 15.1% in 2012–13, increasing the market’s revenues from 3.31 billion USD in 2011-12 to 
3.81 billion USD in 2012–13. Factors such as growing demand for healthcare services, intensive 
R&D activities and strong government initiatives to boost the industry are key to this 
performance. Furthermore, the cost advantage that the Indian firms provide has led to many 
global biotech and pharmaceuticals companies establishing marketing, manufacturing and R&D 
operations in India. The Indian biotech industry holds about 2% share of the global biotech 
industry.  
By 2017, India's biotech industry is estimated to increase to 11.6 billion USD from 4.3 billion 
USD in 2012, growing at a Compound Annual Growth Rate (CAGR) of 22.2%. Presently, India 
is ranked 12th in the world in biotech and third in Asia-Pacific. The Biopharmaceuticals sector is 
the largest contributing about 62%of the total revenue followed by bioservices (18%), 
bioagriculture (15%), bioindustry (4%), and bioinformatics contributing 1% (India Brand Equity 
Foundation, Biotechnology Industry in India, 2014). The Top 20 Indian Biotechnology firms, 
accounted for 47.4% of all revenues in the sector in 2013. 
The Brazilian Biotechnology industry (mainly biotech-crops and Biofuels) and the agriculture 
business combined contribute about 20-30% of the national GDP and provide 37% of the 
country’s jobs. In the health biotechnology sector, Brazil is still very much dependent on imports 
to provide many of its products. This is observed by the deficit in the balance of payment for the 
chemical and health biotechnology sectors (Freire, 2011). Among the 237 biotech firms in 
Brazil, the majority of them are small enterprises (with the large companies having scaled down 
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between 2008-2010 as result of the financial crisis) with only 28% of them having grossed over 
450 000 USD in 2010 (pwc & Biominas, 2011b).  Furthermore, pwc & Biominas (2011) reported 
that 20.6% of Brazil’s biotech firms had no revenues in 2011, 29.1% had grossed not more than 
109 000 USD, and 27% grossed up to 1.1 million USD. Over 46% of these companies had at 
the most 10 employees, while 9.4% had over 100. This study also indicated that in 2011, 38% of 
the Biotech firms had been in business for 2-5 years, while 29% were between 5-10 years and 
18% had been on the market for over 15 years.  
South Africa, a country with such rich biodiversity, highly skilled researcher as well as world-
class research institution and university, trails behind in terms on the contribution of the 
biotechnology sector to its national GDP. To date, no pubic data is available on the economic 
contribution of sector and interviews with local sector experts confirmed this observation. 
Through the interviews, it was clear that of the 58 biotechnology companies that were present in 
2013, only 12% were generating revenues. However, these revenues are not available in the 
public domain. South Africa has to date only had one successful exit in this sector, whereby 
Shimoda Biotech was acquired by a USA based firm in 2008 for an undisclosed amount. 
Section 4.3.1 presents the industry’s composition in terms of the number of companies, 
publically listed companies, revenue generated and number of employees per company in each 
of the selected countries. Section 4.3.2, highlights mainly the economic parameters such as 
percentage GDP spend per country, market size, total profit generated by the industry and 
number and value of M&A in each of these countries. 
 
4.3.1 The Biotechnology sector make-up  
 
From the data presented in Table 4.2 below, it is clear that the USA remains the market leader 
in terms of the number of companies in this sector, with the 2013 number of companies at 2349, 
a number more than any other country investigated in this report. Israel, Brazil, India and 
Switzerland seem to be in the same league ranging between 160 and 240 companies. However, 
within this group, Israel has the highest number of publically listed companies, with 7 of the 60 
listed companies dually listed in foreign markets. The number of South African companies is 6 
times less than that of its emerging market counterparts. The USA, has the highest number of 
publicly listed biotechnology companies at 336 in 2013 compared to any other market, 
testament the maturity of this sector in the USA.  
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Table 4.2: Biotechnology sector composition in the selected markets 
Country parameters Year 
      USA 2005 2007 2008 2009 2010 2012 2013 
Number of Biotech firms 1415 1513 1771 1699 1987 2377 2349 
Number of publically listed biotech firms 293 329 366 313 310 316 336 
Combined revenue generated (billion USD) 50.7 58.7 65.1 56.6 61.1 63.7 71.9 
Average Number of employees per company 126 110 120 109 113 100 109 
       Switzerland 2005 2007 2008 2009 2010 2012 2013 
Number of Biotech firms 137 147 158 161 173 193 220 
Number of publically listed biotech firms 3 3 5 5 9 7 6 
Combined revenue generated (billion USD) 9.2 8.1 8.7 9.3 5.1 4.6 5.2 
Average Number of employees per company 56 69 58 40 37 36 60 
        Israel 2005 2007 2008 2009 2010 2012 2013 
Number of Biotech firms 84 103 119 127 141 154 160 
Number of publically listed biotech firms 18 21 19 20 21 58 60 
Combined revenue generated (billion USD) 33 40 46 50 55 60 62 
Average Number of employees per company 10 10 16 19 20 20 23 
        Brazil 2005 2007 2008 2009 2010 2012 2013 
Number of  Biotech firms 150 183 220 234 250 259 263 
Number of publically listed biotech firms 0 0 1 0 0 0 0 
Combined revenue generated (billion USD) 0.045 0.058 0.089 0.091 0.1 0.12 0.15 
Average Number of employees per company 10 10 10 15 18 25 29 
        India 2005 2007 2008 2009 2010 2012 2013 
Number of Biotech firms 101 113 130 158 170 182 200 
Number of publically listed biotech firms 0 5 8 10 7 9 9 
Combined revenue generated (billion USD) 0.652 0.7 1 1.5 2.4 3.3 3.8 
Average Number of employees per company 350 342 357 400 389 450 550 
42 
 
Table 4.2: Continued 
      Country parameters Year      
South Africa 2005 2007 2008 2009 2010 2012 2013 
Number of Biotech firms 47 38 38 42 47 50 55 
Number of publically listed biotech firms 0 0 0 0 0 0 0 
Combined revenue generated (billion USD) 0.012 0.012 0.027 0.03 0.035 0.038 0.04 
Average Number of employees per company 10 10 8 10 12 14 14 
 
Sources: Al-Bader et al., 2009; Burril Media, 2014, Ernst & Young Global Biotechnology Reports, 2006-2014, Freire, 2011, Frew et al., 2007, 
Make-In-India, Biotechnology report, 2014,Swiss Biotech Reports, 2010- 2014; Torres, 2014, structured expert interviews. 
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In terms of the average age of companies in these markets, the USA has some of the oldest 
companies (older than 20 years). However, 80% of its companies have been in existence for 
10-15 years (Ernst & Young Global Biotechnology Report, 2014). This is a similar scenario with 
the Swiss biotechnology industry. India has about 20% of its companies being older than 15 
years, however the rest are 15 years or less (Frew et al., 2007, Biotechnology Industry report, 
Make In India, 2014). Brazil also has a similar composition as India, with the oldest companies 
of 15 years or more being in crop-biotechnology and biofuels. The majority of the younger 
companies are in health biotechnology (Freire, 2011). Israel on the other hand, has some of the 
youngest companies in this sector; however these companies have performed very well due to 
the government’s focus on this sector and the concentration of multinational companies that 
have partnered with Israeli companies (Zeevi and Alon, 2012). 15% of South African 
biotechnology companies were established prior to 2001, with the rest being established post 
that time, fueled by the establishment of the National Biotechnology Strategy and the respective 
funding agencies (Al-Bader et al., 2009). 
 
The revenue generated in the biotechnology industry is the USA, is a significant contributor to 
the USA national GDP and job creation. Israel’s industry revenues are also significantly higher 
and contribute to the Israeli GDP. Of the three emerging markets studies, i.e India, Brazil and 
South Africa, India has a better performance in this parameter at 4.3 billion USD market size 
2013 compared to (0.96 billion USD in Brazil and 0.065 billion USD in South Africa). However, 
these revenues are still significantly less than revenues in the developed markets. The reported 
revenues for the emerging markets, particularly India, and are further skewed by the M&A 
activity that occurs in these markets by large companies whose revenues are not included in 
this work.  
 
Of the markets studied, this sector provides the highest number of jobs in India. This is mainly 
due to the lower labour costs and the concentration of companies in manufacturing and contract 
R&D for large multinational firms (Frew et al., 2007). In the USA, as much as the sector has the 
highest collective revenues, it does not provide jobs to as many people as in India. Switzerland, 
on the other hand has a similar job creation level to that of Israel, its developed market 
counterpart. The Brazilian average number of employees has fluctuated in the years studies, 
with 2013, having the high average number of employees per company. It is clear from the data 
presented, describing the industry, that albeit the large South African government funding in this 
sector (comparable to India) as discussed in section 2, that this sector remains small in size, 
44 
 
does not provide significant employment opportunities nor revenues that can contribute to the 
national GDP. 
4.3.2 Economic contribution of the biotechnology industry  
 
The economic parameters of the biotechnology industry in the selected markets are presented 
in Table 4.3 below. It is evident from this data that of all the markets studied as presented in 
Table 4.3, the % national GDP spend on R&D has been highest in Israel, sitting at 4.3% to 
3.93% from 2005 to 2013, compared to 2.5-2.8% of the USA and 1.72- 1.82% of Switzerland. 
This significantly higher contribution explains the current strength of the Israeli biotechnology 
sector (Zeevi and Alon, 2012, WorldBank Indicator http://data.worldbank.org/indicator/GB 
accessed 13 February 2015). For the three emerging markets reviewed, i.e India, Brazil and 
South Africa, the %GDP spend on R&D is lower or equal to or slightly above 1%. Although India 
has a low % GDP spend, the contribution by the private sector through M&A, and JV’s fuels 
growth of the industry.  
 
The USA remains the largest market in this sector with 2013 total revenues generated sitting at 
71.9 billion USD, followed by Israel with 2013 revenues at 62 billion USD. The revenues 
generated in emerging markets as discussed above, is still significantly lower. The total R&D 
costs as a percentage of revenue are consistent in the industry, since biotechnology is typically 
an R&D intensive industry. India has positioned itself as a global center of contract R&D that 
provides lower cost R&D, attracting many multinational companies to partner with Indian 
companies (Frew et al., 2007). This approach has also enabled India to attract foreign 
investment into biotechnology related infrastructure development and attract highly skilled 
researchers. 
 
The concentration of multinational companies in the USA, Switzerland and Israel, provide an 
exit strategy that supplements the IPO route. This is observed by the high number of M&A 
activities in these markets with significant value. Again, the USA still leads in this aspect, 
followed by Switzerland. India experienced a spike in M&A activities in 2009. This was driven by 
a number of large multinational companies that partnered with India biotech companies in an 
effort to reduce their R&D costs and access innovative products in the midst of budget cuts 
during the financial crisis (Ernst & Young Global Biotechnology Report, 2010). 
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Table 4.3: The economic parameters of the biotechnology industry in the selected markets 
Country parameters Year 
      USA 2005 2007 2008 2009 2010 2012 2013 
%National GDP spend on R&D 2.5 2.63 2.77 2.82 2.74 2.72 2.8 
Total profit generated (billion USD) 0.1 0.2 0.4 3.7 5.2 4.5 2.6 
Total revenues generated (billion USD) 50.7 58.7 65.1 56.6 61.1 63.7 71.9 
Total R&D costs (billion USD) 19.8 20.1 22.6 17.2 18 19.3 23.3 
Total government funding 370 430 460 380 400 450 500 
Number of M&A activities 13 14 15 18 13 11 4 
Value of M&A or JV's (Billion USD) 10 17.2 12 25.4 10 3.1 9.9 
Number of IPOS 13 18 1 3 15 12 41 
Value of IPOS (billion USD) 0.62 1.24 0.006 0.7 1.1 0.76 3.2 
Size of VC funds raised (billion USD) 3.8 5.9 4.4 4.7 4.4 4.1 5.6 
       Switzerland 2005 2007 2008 2009 2010 2012 2013 
%National GDP spend on R&D 1.72 1.75 1.75 1.82 1.77 1.8 1.82 
Total profit generated (billion USD) 0.02 -0.03 0.1 0.1 0.5 0.16 0.25 
Total revenues generated (billion USD) 9.2 8.1 8.7 9.3 5.1 4.6 5.2 
Total R&D costs (billion USD) 2.2 1.8 2.1 2.2 1.3 1.3 1.3 
Total government funding (million USD) 89 63 39 49 40 45 47 
Number of M&A activities 9 8 7 11 7 5 5 
Value of M&A or JV's (billion USD) 0.3 0.25 0.19 0.32 0.21 0.21 0.22 
Number of IPOS 2 0 0 0 0 2 0 
Value of IPOs (billion USD) 0.6 0 0 0 0 0.3 0 
Size of VC funds raised (billion USD) 0.3 0.18 0.2 0.14 0.2 0.3 0.33 
        Israel 2005 2007 2008 2009 2010 2012 2013 
%National GDP spend on R&D 4.3 4.52 4.4 4.17 3.97 3.93 3.93 
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Table 4.3: Continued        
Country parameters Year       
Israel        
Total profit generated (billion USD) 0.03 0.09 0.097 0.1 0.12 0.15 0.2 
Total revenues generated (billion USD) 33 40 46 50 55 60 62 
Total R&D costs (billion USD) 1.2 1.34 1 1.4 1.45 1.3 1.42 
Total government funding (million USD) 80 100 160 180 220 240 270 
Number of M&A activities 3 2 4 4 3 2 3 
Value of M&A or JV's (billion USD) 0.57 0.6 0.93 0.88 0.433 0.7 0.712 
Number of IPOS 4 4 2 3 1 3 3 
Value of IPOS (billion USD) 0.7 0.6 0.15 0.28 0.15 0.5 0.2 
Size of VC funds raised (billion USD) 0.043 0.053 0.048 0.041 0.052 0.075 0.082 
        Brazil 2005 2007 2008 2009 2010 2012 2013 
%National GDP spend on R&D 0.9 1.01 1.1 1.17 1.16 1.16 1.18 
Market size (billion USD) 0.3 0.35 0.4 0.6 0.8 0.89 0.96 
Total profit generated (billion USD) 0.04 0.0445 0.055 0.065 0.07 0.067 0.076 
Total R&D costs (billion USD) 0.05 0.054 0.06 0.07 0.072 0.077 0.076 
Total government funding (million USD) 980 101 105 105 108 110 110 
Number of M&A activities 3 2 3 5 3 6 8 
Value of M&A or JV's (billion USD) 1.5 1 1.8 1.01 0.8 2 2.5 
Number of IPOS 0 0 0 0 0 3 0 
Value of IPOS (billion USD) 0 0 0 0 0 0.8 0 
Size of VC funds raised (billion USD) 0.08 0.1 0.3 0.5 0.7 0.5 0.2 
        India 2005 2007 2008 2009 2010 2012 2013 
%National GDP spend on R&D 0.7 0.76 0.8 0.8 0.8 0.8 0.9 
Market size (billion USD) 1.5 1.9 2.6 2.6 3 4.3 4.3 
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Table 4.3 Continued        
Country parameters Year       
India        
Total profit generated (billion USD) 0.01 0.011 0.014 0.02 0.024 0.026 0.029 
Total R&D costs (billion USD) 2 2.6 2.4 2.3 2.7 2.8 3 
Total government funding (million USD) 250 290 290 295 350 340 340 
Number of M&A activities 3 3 2 6 5 4 5 
Value of M&A or JV's (billion USD) 0.4 0.35 0.3 0.8 0.5 0.6 0.8 
Number of IPOS 0 5 9 3 1 2 1 
Value of IPOS (billion USD) 0 0.5 0.12 0.226 0.15 0.23 0.12 
Size of VC funds raised (billion USD) 0.06 0.08 0.1 0.15 0.12 0.1 0.15 
South Africa 2005 2007 2008 2009 2010 2012 2013 
%National GDP spend on R&D 0.93 0.92 0.93 0.87 0.76 0.85 0.93 
Market size (billion USD) 0.062 0.05 0.06 0.062 0.062 0.065 0.065 
Total profit generated (billion USD) 0 0 0.001 0.001 0.0016 0.0018 0.002 
Total R&D costs (billion USD) 0.098 0.098 0.1 0.12 0.12 0.13 0.15 
Total government funding (million USD) 19.95 24.5 23.4 28.5 32.6 35 38 
Number of M&A activities 0 0 1 0 0 0 0 
Value of M&A or JV's (Million USD) 0 0 NA 0 0 0 0 
Number of IPOS 0 0 0 0 0 0 0 
Value of IPOS (millions) 0 0 0 0 0 0 0 
Size of VC funds raised (billion USD) 0 0.05 0.04 0.04 0.03 0.03 0.02 
Sources: Al-Bader et al., 2009; Bonalume et al., 2006; Burril Media, 2014; Dept. of Science and Technology, National Biotechnology Audit 2007; 
Dept. of Science and Technology Ministerial Report on BRICS, 2011; Ernst & Young Global Biotechnology Reports, 2006-2014; Freire, 2011; 
Frew et al., 2007; Gouviea, 2012;  India Brand Equity Foundation, 2014; Make-In-India, Biotechnology report, 2014; Pwc & Biominas, 2011b; 
Rezaie et al., 2008; Singh 2007; South African NACI, 2013; Swiss Biotech Reports, 2010- 2014; Swiss Venture Capital Report, 2015; Torres, 
2014; World Intellectual Property Organisation, 2014, www.wipo.org; Zeevi and Alon, 2012. Expert interviews with practitioners from IDC (VC and 
Health SBU’s), TIA (Biotechnology Unit), DST and previous CEO’s of the Biotechnology Regional Innovation Centres. 
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Being an established, open and mature market, the USA has had the highest number of IPOs in 
this sector compared to other markets studied in this work. The years 2007 and 2013, have to 
date been two of best performing years, based on the number of IPOs and the value of the 
IPOs. The rest of the markets, i.e both developed and emerging markets, are not large enough 
in terms of companies that are close of IPO, size of the stock markets and the investor appetite 
for this sector to have as many IPOs as the USA. Although South Africa has a mature stock 
market, there has not been any IPO listing in the time analyzed in this thesis. This reflects the 
low risk tolerance of the South African investment sector, a limited number of companies that 
are mature enough for IPO listing and the small size of the industry (Ernst & Young South 
African Biotech Review, 2006; Al-Bader et al., 2009). The Swiss biotech industry, although 
mature, due to its size (number of companies) has not had many IPOs listings recently, with the 
maximum being two per annum.  
 
It clear from the data presented in section 4.3.1 and 4.3.2 that South Africa trails behind in this 
sector. The next section focuses on understanding the funding environment in these markets to 
explain the observed economic performance.  
4.3.3 Funding environment 
In 2001, the department of science and technology in SA established the National 
Biotechnology strategy which allocated 58 million USD to the sector between 2004-2007 (2007 
National Biotechnology Audit). These funds were channeled through the Biotechnology 
Regional Innovation Centers. The South African Biotechnology ventures are still highly reliant 
on government funding, with the Technology Innovation Agency (TIA) and the Industrial 
Development Corporation (IDC) being the largest funding institutions for dispersing government 
funds in this sector. The IDC invested a total of 21.5 million USD in 12 biotechnology companies 
between 2007 and 2013, with TIA having invested a total of 10 million USD since 2009 
(Interviews with sector experts). These funds are generally structured as grant funding, equity 
funds or loans as well as performance-linked loans. 
Based on the interviews carried out, 80% funding is grant funding. The only venture capital firm 
that was active in Biotechnology investment was Bioventures, which raised a total of 8 million 
USD (small compared to those of other companies internationally) during its existence from 
2001-2008 and invested in 8 companies. In the seven (7) years of its existence, it invested 
typically between 750 000 – 1 million USD in these companies, five (5) of which are still in 
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existence and generating some revenues (Al-Bader, 2009 and expert interviews). The limited 
number of biotechnology dedicated VC firms, means that the risk is assumed by one major 
funder and is thus not spread. 
When comparing the size of the government funds available for investment in South Africa, it is 
evident that these funds (mainly seed capital from government) are spread too thin to have a 
significant impact and there is limited funds available for series B funding. Private financing in 
biotechnology sector in South Africa is very limited and is clustered under healthcare, 
agriculture or manufacturing sectors. As presented in the annual Venture Capital and Private 
Equity Industry performance survey of South Africa for 2013, of the 1.75 billion USD total private 
equity or venture capital funds only 2% were for healthcare investments. This funding gap is 
mainly due to lack of strong venture capital tradition in South Africa, a shortage of investors who 
understand the biotechnology sector, risk aversion, limited success story in the biotechnology 
sector as the higher returns on investments that are available in other sectors (Al-Bader et al., 
2009, KPMG and SAVCA.(2014). Venture Capital and Private Equity Industry Performance 
Survey covering the 2013 year) Furthermore, the relative absence of a strong domestic 
pharmaceutical manufacturing sector in South Africa compared to countries such as India and 
Israel, puts it in a lower league to these markets. This factor can also explain the low private 
sector investment in this sector in South Africa. 
The Indian financial environment, has improved over the past year. However, the risk-averse 
nature of bankers and investor in India has limited the number of investment made in this 
sector. Some local investors as well as government, through the Andhra Pradesh Industrial 
Development Corporation and the Industrial Credit and Investment Corporation of India Venture 
have made significant stride into increasing the pool of funding available. For example, India’s 
Dept of Science and Technology invested over 34 million USD between 2004-2005 comparable 
to South Africa’s 58 million USD investments by its Dept of Science and Technology between 
2004-2007. A few members of the India Venture Capital Association (IVCA, 
http://www.inidanvca.org/) see Biotechnology as an industry to invest in. The success of some 
Indian Biotech firms such Biocon, Shantha Biotechnics and Wockhardt, have led to US based 
investors having interest in Indian Biotech firms, as depicted in Table 4.3 by the VC funds raised 
within the period studied (Frew et al., 2007). 
In 2012, six Israeli biotechnology firms were financed by venture capital firms to a total of 9 
million USD compared to 4 companies at 5 million USD in 2011 (See Table 4.3). In the 
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biotechnology sector, about 50-70% of these investments are geared towards seed and early 
stage companies, whereas for high tech sectors, it is mainly early and mid-stage companies. 
The medical devices sector, still remains as the sector that attracts the most VC funds.  
Similar to South Africa, private financing in Brazil for the biotechnology sector remains limited, 
with most firms relying on US based companies to avail these funds. Thus, for most 
biotechnology firms in Brazil, government agencies such as the Financing Agency for Studies 
and Projects (FINEP) and development banks, which offer low interest rate loans (Brazilian 
Development Bank) remain the major funder in this sector. In September 2006, FINEP provided 
70 million USD for drug development projects that resulted in four health biotechnology 
receiving significant funding (Bonalume, 2006). However, government funding in Brazil comes 
with conditions that most companies do not favor. These include, not being able to use the 
funds provided by FINEP outside Brazil and the requirement to get permission from FINEP in 
the event that a company considers licensing a technology. These aspects have thus, limited 
the impact of government funding in this sector (Gouveia, 2012). A few companies in Brazil 
have been able to raise funding from Brazilian VC. The main organization that provides VC 
funds is CRIATEC, which supports emerging enterprises that show growth potential. CRIATEC 
has to date supported 36 companies since its inception in 2008. It administers funds from public 
institutions such as the National Bank for Economic and Social Development (BNDES) and 
BNB. Other VC funds in this market have been raised from companies such as Burril Brasil (a 
subsidiary of Burril &Co in the USA), INOVA biotechologia and Braskem Petrochemical. As 
depicted in Table 4.3, during the period between 2008-2013, and 2.2 billion USD was raised 
through VC funds. However, in the past three to four years, most of these have been availed to 
companies in crop biotechnology (Rezaie et al., 2008). A key reason for this is that there is lack 
of a viable exit strategy available to VC and angel investors that invest in health Biotech. Thus, 
similar to South Africa and India, to grow this sector would require an IPO market or a good 
presence of large multinational or local companies that a willing to set up M&A or JVs with the 
SME’s in this sector. 
In Switzerland, the funding of R&D as well as commercialization of technologies comes from 
three main sources, Swiss National Science Foundation (SNSF), the Commission for 
Technology and Innovation (CTI/KTI) as well as private funding. Like other markets there is 
limited private funding for biotechnology, however, what stands Switzerland in good stead is that 
the environment is conducive to establish biotechnology firms due to the strong pool of financial, 
R&D and legal skill sets required for establishing successful companies and the history of 
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having successful biotech firms (Swiss Biotech report, 2014). According to the Swiss Venture 
Capital Report, January 2015, about 450 million USD VC funds were invested in start-ups in 
Switzerland, with more than three quarters (approximately 355 million USD) of the fund been 
allocated in the life sciences industry. Biotech received funding to a total amount of 189.6 million 
USD (42% of the total VC funds), the largest investment in the life sciences industries. 
The USA remains as one of the market leaders in terms of financing biotechnology start-ups as 
well as having a number of options available for a company to access funding. According to the 
Ernst & Young 2013 report, after the 2008 financial crisis, funding for biotech firms has been on 
an upward trajectory. During this period of 2010-2012, debt funding increased significantly from 
5.6 billion USD in 2008 to 11.8 billion USD in 2012, mainly due to debt accumulated by larger 
firms. VC and IPOs did however; experience a minor down turn as indicated in Table 4.3. 
Similar to Switzerland, the biotechnology sector in the US is well funded through VC. 
The level of funding geared towards Biotechnology start-ups in SA, versus the countries it is 
compared to in this thesis in very low. On average, a typical South African SME receives 1.4 
million USD of series A funding compared to 5 million USD in Europe and 10 million USD in the 
USA. For Series B, it is 2.5 million USD for South Africa, 15 million USD and 20 million USD for 
Europe and the USA respectively (Ernst & Young, South African Biotech Review, 2006). 
Furthermore, as observed from the funding environment in the various countries, there is much 
less VC and PE funding available for the sector in South Africa, however the level of 
government funding is on par with that of India. Thus, the question becomes, how can the 
government funds that are available be structured to yield a return on the investment made in 
this sector? In addition, what other factors result in successful financial performance of this 
sector in markets such as the USA, Switzerland, India and Israel. Thus, the next section 
highlights and discusses the important elements that contribute to the success of the sector. 
4.4. Elements that contribute to positive financial performance of the 
biotechnology sector 
4.4.1 Involvement of Universities 
The role of the Universities and their involvement is important in the context of understanding 
the investment performance of this sector, in that the listed biotechnology companies that 
contribute significantly in this sector such as Amgen, Genentech, and Biogen in the USA 
(discussed in Chapter 2) were all founded from university based technologies by university 
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employees. A majority of these companies have previous employees of universities as 
CEO/CSO and have entrepreneurs as CEOs.  
The South African Biotechnology companies are 40% University spin offs, that is companies 
founded from technologies emerging from Universities and not necessarily run by a university 
employee and innovation start-ups, which are technologies not necessarily emerging from 
universities. Companies such as Altis Biologics, Arvir Technologies, Elevation Biotech were 
started off from Universities or Science Councils, however they still represent a small number of 
companies that were university Spin-offs. In Israel on the other hand, a majority of 
biotechnology firms emerged from universities, and this is mainly driven by high concentration of 
scientist per capita (145 per 10 000) as well as a number of successful university spin-offs that 
can absorb the human capacity. These companies include BioSense, Syneron and Teva 
Pharmaceuticals to name a few which have proven to be successful by producing a number of 
internationally acclaimed blockbuster drugs and some of which are listed in the NASDAQ (Zeevi 
and Alon, 2012).  
Similar to Israel, a majority of Indian biotech firms emerged from Universities and are still 
heavily reliant of universities for their R&D. In addition, these partnerships provide advanced 
training and help develop specialized and qualified work force in the industry. These 
partnerships are not limited to local universities, but extend to international partners with the 
focus being on developing products for the emerging markets and low cost production of 
relatively expensive products in an effort to improve access to medicines (Frew et al., 2007).  
Freire, (2011) reported that as much as 94.5% of Brazilian biotechnology firms have 
relationships with universities and research institutions, for the main reasons of development of 
innovative products, access to infrastructure and resource sharing as well as access to highly 
skilled human capacity.  
Swiss Universities are well-established centers of excellence in the biotechnology field, where 
by approximately 90% of Swiss Biotechnology companies have university collaborative projects 
or emerged from universities (Swiss Biotech Report, 2013). Universities such as the Swiss 
Federal Institutes of Technology in Zurich (ETHZ) and Lausanne (EPFL), the University of 
Basel, Bern and Geneva are some of a few which have numerous partnership with the private 
sector. Furthermore, these universities tend to be technology hub and incubation facilities for 
most Swiss biotechnology SMEs. An example of a successful university – private sector is that 
of ETHZ and Norvatis. In this case, Norvartis will establish the seed fund not expecting to be 
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paid back for the fund but rather sees it as a mechanism to improve its pipeline of innovative 
products that will keep it ahead of its competitors (Swiss Biotech Report, 2013). 
The US government played a significant role that led to the USA being a market leader in this 
sector. The government supported the industry through funding basic science research though 
institutions such as the NIH, relaxing the government control over the commercial use of the 
outcomes of publicly funded research through the Bayh-Dole Act of 1980 and the provision of 
strong IP protection. The biotechnology industry originated in the USA Universities, primarily in 
the state of California, where researchers exploited the commercialization of knowledge and 
tools in the DNA technologies. Many of the initial biotechnology firms were established by 
university scientist. One of the most successful was Genentech which was established by a 
scientist from University of California, San Francisco (Prevezer, 2001). To date, many 
biotechnology firms in located in the university-technology cluster regions such as California, 
Massachusetts and New York testament to the critical role of the universities in these regions. 
When compared to other countries such as the USA, Israel and India, it is clear that there is 
significantly less University spin-offs in South Africa with ex-university employees as CEOs. This 
observation could be a factor of the nature and culture of South African universities which are 
generally not geared to commercialize innovations stemming from the R&D and spinning off 
companies. Thus, this begs the question: in addressing poor economic performance of the 
sector, what role should South African universities be playing and how should they be structured 
to realize the desired outcomes? 
4.4.2. Contribution of patents to the global market 
Patents are important in this sector as income generated from licensing proprietary technologies 
represents a growing part of the total revenues of companies in this sector. Patents also serve 
an important role in demonstrating to potential investors the company’s technical competencies 
and the ability to keep competition at a distance. For example, VC firms almost exclusively 
invest in patent holding biotechnology firms as this intangible asset serves as collateral. 
In South Africa, prior to the establishment of the IPR act, which is based on the Bayh-Doyle Act, 
difficult and protracted IP negotiations used to limit commercialization ventures as well as 
partnerships with the private sector. However over the years, this trend has changed, resulting 
in South Africa’s world share of patents increasing. However patents within this sector are still 
very few sitting at 34 patents granted in 2011 compared to 85 patents granted in India over the 
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same period. (South African National Advisory Council on Innovation (NACI) on South African 
Science and technology indicators, 2013).  
Israel’s life sciences patent position is very strong with its number of patents per million capita in 
the medical devices field in first position globally and biotechnology number of patents per 
capita giving it a second place ranking (Zeevi and Alon, 2012 ). This aspect, as well as Israel’s 
openness to alliances and partnership has helped boost the commercialization of patented 
products. 
India on the other hand, is a country where the administration of the patent systems is poor, in 
that the assessment of patentability is not in line with the other major economies and the use of 
compulsory licensing, has limited the interest of multinationals to partner with Indian firms 
(Burrill Media, 2014. Accelerating growth: Forging India’s Bioeconomy). However, this aspect 
has improved, resulting in an increase in the number of Indian originating patents in this sector. 
Brazil has emerged as one of the leading countries in patent applications in the organic 
chemistry and pharmaceuticals sector, whereby in 2011 it accounted for 2.7% of all patent 
publications in the world in these two areas as well as 1.6% of biotechnology patents, compared 
to 1% and 0.6% in 2010 respectively. However the 2012 performance was poor at 0.8% and 
0.5% respectively (World Intellectual Property Organization, 2014). The patent applications in 
the period of 2008-2010 were significantly affected by the financial crisis as also seen by the 
number of companies that downsized between 2008-2010 (pwc & Biominas, 2011b). 
Switzerland generates a fraction of the worldwide patents, however per capita the country is 
among the highest in the world. . The number of patents published each year by US assignees 
is about a third of the Swiss rate. The USA on the other hand remains the market leader in 
number of patents published.  
4.4.3. Alliance with large corporates and multinational companies 
For large multinational companies in the USA and in Switzerland alliances are critical since the 
organizational structure, regulations and processes of these large corporates, limit their ability to 
pursue R&D for innovative products. Thus, SMEs and universities in the biotechnology sector in 
both these countries tend to present an avenue for these large corporates to outsource R&D. 
Thus, while evaluating the performance of investments made in this sector, it is important to 
measure the impact of such alliances. 
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Although South Africa has healthy presence of multinational companies in biotechnology related 
fields such as pharmaceutical companies, agro-processing and medical devices and diagnostics 
companies, very limited alliance and R&D partnerships occur. One of the barriers in this regards 
is the “academic mindset” that is still heavily entranced in universities, where very little applied 
and commercial R&D is conducted (Al-Bader et al., 2009). Even though there is strong interest 
from private sector to partner with South African Universities and start-ups in this sector, the 
difficulty of doing business in the country is limiting (i.e slow regulatory processes leading to 
long time lines to approve products and clinical trial and limited know-how in regulating 
new/innovative products and the absence of a research-based pharmaceutical industry). 
Israel has a strong representation of multinational companies who have formed R&D alliance 
with local companies and partnerships with local university with the aim of conducting R&D for 
new products to remain competitive. These multinationals include Johnson & Johnson, GE 
Healthcare, Merck Serono, Phillips, Abbot and MSD and Edwards LifeSciences. The extent of 
the partnerships includes provision of seed capital, access to world class infrastructure by the 
Israeli start-ups and human capacity development. An example is Merck Serono, which in 2011 
established a strategic bio-incubator fund in Israel with a budget of 10 million Euros (Zeevi and 
Alon, 2012).   
The technological strength of Indian biotechnology firms allows for joint ventures with 
multinational companies. An example is the joint venture between Biocon and a Cuban 
pharmaceutical company CIMAB to develop monoclonal antibodies for cancer treatment. This 
JV has further enabled the establishment on a manufacturing facility for a range of therapeutic 
compound that were not manufactured in India before. In addition, foreign firms interested in 
tapping into the large Indian market partner with local firms for their distribution networks, 
knowledge of the local regulatory landscape and legal system. An example is a company, 
Nicholas Piramal which distributes products for Roche, Gilead and Genzyme (Frew et al., 2007). 
Since the majority of Brazilian biotech firms are small and micro enterprises that are pre-
revenue or only generated on average 450 000 USD, going through the entire R&D value chain 
proves to not be feasible. Thus, partnerships and alliances with both local and international 
firms are critical. An Example is Pfizer’s investment of 27 million USD in increasing production 
capacity in Itapevi, Brazil. In addition, Pfizer is also planning to add approximately 20 innovative 
medicines to its portfolio which will be produced in Brazil. This is significant investment that 
benefits not only Pfizer, but the Brazilian biotechnology industry (Ernst & Young, Global Biotech 
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Report, 2012). In April 2014, a number of companies including Amyris, BP, Dow Chemical, 
DuPont, and Novozymes came together to launch of the Brazilian Industrial Biotech Association 
(ABBI) to promote dialogue with stakeholders, policy makers, and the public about advancing 
industrial biotechnology in Brazil. The trade group aims to improve current patent laws in light of 
new biotechnology advancements, support investments in R&D, laboratory infrastructure, and 
capacity and training for skilled and technical labor, an effort which is envisioned to significantly 
contribute towards enabling biotechnology enterprises (Torres, 2014).  
4.4.4. Stock market activity and diversity 
In South Africa, although the Johannesburg Stock Exchange (JSE) is well regarded in the 
financial markets, there are currently no biotechnology ventures listed (KPMG and SAVCA 
report (2014). Venture Capital and Private Equity Industry Performance Survey covering the 
2013 year), and thus, it means that listing on the JSE is not a viable option for the SA 
Biotechnology companies which are to date all private companies. Thus, this limits the exit 
strategies of most biotechnology companies in SA (Al-Bader et al., 2009). This is further 
observed by the fact that in 2013, there were no IPOs in South Africa (even alternative 
industries) compared to the 20 million USD value IPOs in 2012 (Ernst & Young, South African 
Biotech Review, 2006). 
On the Tel Aviv stock exchange (TASE), the life sciences sector (i.e Pharmaceuticals, medical 
devices, Biotechnology, Agriculture biotechnology and Medical IT including health services) is 
the largest sector with 58 companies listed. Of these, 7 are dually listed in the foreign markets, 
where 4 of these are listed on NASDAQ (Zeevi and Alon, 2012). 
Rezaie et al., (2008) reported that at the time of that study, only one health biotechnology 
company, BIOMM Technology was listed on the Brazilian Stock Exchange (BOVESPA), with the 
rest being large agriculture biotechnology business. There was however, a number of 
companies that were preparing for listing in the BOVESPA-MAIS that targets investors with a 
longer investment time horizon which is ideal for the biotechnology sector considering its long 
development time-lines. In 2013, the number of health biotech firms listed had not increased, 
but three (3) large agriculture focused companies had been listed on the BAVESPA-MAIS 
(Ernst & Young, Global Biotechnology Report, 2014). 
In India, there was no listing or IPO between the period of 2000 to 2007, with the first listing in 
2007 being that of Saamya Biotech (Singh, 2007). Generally, the India biotechnology sector had 
an aversion to listing, whereby even established companies such as Bharat Biotech 
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International Ltd or Serum Institute of India Ltd have not made IPOs, but raised funding through 
government funds. Singh (2007) posits that the main reason for this aversion is that the Indian 
stock market is not in a position to value potential based on intellectual property or a novel 
algorithm or a new technique. However, has since had a total of 20 IPOs. The current number of 
listed biotechnology firms in India is 9, with number of the companies having delisted due to 
M&A or JV buy-outs. 
Switzerland has a long tradition of financing life science stocks, but also unlike the emerging 
markets, has the expertise like the USA in valuing biotech stocks. The SIX Swiss Exchange 
provides a potent capital market that attracts a number of investors. To date, the SIX Swiss 
Exchange has 6 listed biotechnology firms. The high concentration of funds in Swiss banks 
benefits most companies when it comes to raising funds in the public capital markets. As a 
result of the financial sectors strong focus on the life sciences, the SIX Swiss Exchange sector 
indices, SXI LIFE SCIENCES and SXI Bio&Medtech, have shown outstanding performance 
compared to foreign benchmarks (Swiss Biotech report, 2010). 
This market place provides an avenue for investment opportunities as well as exits for VC and 
angel investors. Thus, the lack of a vibrant, well capitalized market for the biotech sector limits 
the investment opportunities. This is clearly observed in the South African and Brazilian context.  
4.4.5. Exit options 
Israel has very active M&A environment, whereby since 2005, 23 life science companies were 
acquired by multinationals that have a presence in Israel such as Johnson & Johnson and 
Abbott or even those that did not have a physical presence in the country. The range of the 
deals was between 40- 438 million USD each. However, of these 23 acquisitions, only 2 were in 
the Biotechnology sector and a majority in medical devices (Zeevi and Alon, 2012). These 
successful transactions provide an active sphere for investors to exit, thus boosting the 
availability of funding for seed and early stage funding.  
The average return in Israel for sector is 151.4 USD with an average multiple of about 12. The 
average time to exit from the first government or institutional round of investment is 8 years. 
When compared to emerging markets such as India, Brazil and South Africa, this time frame is 
short, but when compared to other high tech industries this is long. However, taking into account 
the time it takes to develop a biotechnology product, this time frame is reasonable. Due to the 
long times lines of biotechnology investments, in order to attract more biotechnology companies 
for listing, TASE reviewed its listing requirement and adjusted the costing accordingly in 2005. 
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This led to an influx of life science companies, addressing a large financing gap in the industry, 
while providing transparency and liquidity to a wide investor audience that was previously not 
exposed to this sector (Life Sciences in Israel, Ministry of Industry, Trade and Labor, 2013). For 
these companies, a new index, referred to as the BioMed Index was established in 2010.  
Much of the partnering and M&A activity in India is centered on generic drug makers. However 
recently, i.e between 2009 and 2013, there has been some M&A activity in the Biotechnology 
sector. These include, Sanofi’s (one of the large multinational pharmaceuticals company) 2009 
acquisition of Shantha Biotech and Biocon’s partnership with Sanofi and Norvatis. When 
compared to market such as Israel, there is limited M&A activity in India in this sector, thus 
limiting the investment appetite by various funders or institutions (Burril Media, Accelerating 
growth: Forging India’s Bioeconomy, 2014). Other factors mentioned in this report are that 
foreign companies or investors are concerned about the relative lack of predictability and 
transparency in regulations affecting these transactions as well as taxation and profits 
repatriation. The manner in which India handles IP including concerns about patent theft 
remains a challenge that limits M&A or other investment deals in India. 
4.5 Challenges that limit sector growth in South Africa 
Many other non-financial and non-economic factors can be attributed to this overall poor 
industry performance. Based on the interviews a number of factors discussed below emerged 
consistently as being hindrances. The lack of industry specific management experience: This 
industry is dominated by researchers who have limited management experience. Thus, when 
these individuals start-up companies and assume the role of CEOs, the companies fail due to 
lack of business skills. A specific example is that of Persomics, a company that was supported 
by the IDC, who had to eventually terminate their support, due to the CEO not having the skills 
set to position the company such that it is successful and partners with the right type of 
international companies. The CEO has subsequently resigned from the company and the 
institution where this technology emerged from has since formed a JV with a US based 
biotechnology company (Based on interview with the IDC).  
 
The academic approach of most R&D conducted in the South Africa is problematic: The norm is 
that R&D is conducted to generate new knowledge, publications and train students, without 
having to exploit the commercial potential of technologies. Thus, researchers do not have a 
commercial mindset. Furthermore, the academic nature of the R&D has led to the general 
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research community striving to develop perfect products, whereas as observed in the USA, 
even at IPO, some the biotechnology companies do not market ready products at that stage. 
There is a use of incorrect funding instruments to catalyze commercialization. With most of the 
funding in the sector being provided by government there are competing priorities between 
funding R&D to train and generate knowledge and providing funding for commercialization 
purposed. Even with the funding allocated to develop commercial enterprises, the instruments 
applied are inadequate and the involvement of the funder’s management team in assisting to 
commercialize the enterprise is non-existent.  
 
There is a lack of a vibrant VC sector. Although SA does have a number of VC companies, the 
long times lines and high risk nature of this industry limits the investments as most investors are 
not as risk-tolerant and patient. Furthermore, there is a lack of understanding of the 
biotechnology sector by the average investment manager. This lack of understanding and 
experience of the sector creates a bias towards the well understood sectors, where the average 
investment manager would choose to invest in the well know industry that have a proven track 
record.  
 
There is a limited presence of large corporates that develop innovative products locally: This 
situation hampers the growth of this industry in two ways. Firstly, there is no taker for the 
innovative R&D that is conducted locally. Secondly, there is no industry partner to exit through, 
deterring investors who are looking to exit at some point. 
 
Lack of Series B and C funding. Even though seed capital is limited, most companies do 
manage to raise it from the various institutions present, i.e TIA, IDC, the dti. However, when the 
companies require large funding amounts in the order of 5-10 million USD, there are generally 
no or limited avenues to access this amount of funding 
 
Thus, in developing innovative funding models that would spur growth in this sector and in 
addressing the various elements mentioned in section 4.4 that contribute to a positive economic 
performance of the sector, these additional challenges need to be addressed. 
 
60 
 
4.6 Chapter summary 
 
The data represented in this work illustrates that when compared to the development markets, 
the composition of the SA biotechnology sector lags behind in terms of the number of 
companies that are in existence. Even though the South African companies are increasing per 
annum at an average growth rate of 2.5%, the growth rate is much less than that of developed 
markets analyzed (i.e 9% average annual growth rate in the USA and 12% in India). Although 
the JSE is comparable in terms of size and liquidity to for example the TASE (473 companies 
and 339 million USD daily turnover in equity markets), South African has no Biotechnology 
listings. Furthermore, the revenue generated in this sector in South Africa, by a handful of 
companies is much less than the revenues in all the countries studied. In all the countries 
studied, the biotechnology industry is a significant contributor to the GDP as discussed in 
section 4.3. It is well understood that the biotechnology industry does not generate as much 
jobs as other sectors such as mining and banking service, however, compared to its emerging 
markets counterparts, the number of employees per company in SA is almost 10 times less.  
The economic performance of the South African biotechnology industry, when reviewed along 
the parameters detailed in Table 4.3 and chapter 4 performs poorly. Although the percentage 
national GDP spend on R&D is within the ranges of SA’s emerging markets counterparts, i.e 
Brazil and India, the market size, industry revenues and profits generated are much less than 
these markets. Secondly, only one (1) acquisition in the period studied took place, no IPOs and 
limited VC funds were raised. Lastly, it is evident that government funding in this sector is on par 
with that of India and Brazil, however the lack of private sector funding is much more 
pronounced in South Africa.  
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Chapter 5: Conclusions and Recommendations 
5.1  Introduction 
The objective of this thesis was three fold. First to make a comparative performance analysis of 
the South African biotechnology Industry and developed and emerging markets. Second to 
determine the investment performance of biotechnology companies in South Africa compared to 
other markets and last to investigate the appropriate financing model for South Africa that would 
result in significant growth. This chapter is organized as follows. Section 5.1 presents the 
discussions Section 5.2 concludes the report. 
5.2 Discussion 
 
As discussed in section 2.2, the biotechnology industry is characterized by high cost and high 
risk innovation and has emerged as a prototype industry for commercialization of scientific ideas 
and provides lessons for the processes and mechanisms involved in technology 
commercialization (Prevezer, 2001). Development of biotechnology products, particularly in the 
pharmaceutical sector has been characterized by extremely long development times and high 
development costs. Furthermore, it was presented in chapter 2 that in the past, governments 
have played a major role as catalyst in this sector, through providing innovative funding models, 
establishing legislations that enable SME development and growth, as well as IP legislation that 
is supportive of innovation and partnerships. Lastly the governments have played a major role in 
attracting multinational companies who are important players in the ecosystem.  
 
As discussed in section 2.5.1 biotechnology firms, similar to various SME’s are not immune to 
funding challenges. Typically, these firms experience challenges in the late stage R&D phase, 
where research or government grants are no longer the relevant instrument for financing and 
the late stage business development phase where they need to grow and they require late 
stage equity capital. These gaps have led to failure of many biotechnology start-up. As 
observed in the results presented in section 4.3.2, established and mature markets such as the 
USA, Switzerland and Israel, where VC funding and funding that comes from M&A deals is 
much larger than in emerging markets, the industry have a much stronger company 
composition. This is observed in terms of number of companies, jobs created and number of 
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companies publically listed which are much higher in developed markets than in Brazil, India 
and South Africa. 
 
The work presented in this thesis, indicates, that in addition to the funding requirements, there 
are critical elements that contribute to the positive economic performance of the biotechnology 
industry. These elements include the involvement of Universities, whereby, as discussed in 
section 4.5.1, this a critical aspect that fosters innovation and growth of number of companies, 
thus resulting in the industry demographics presented in Section 4.3.1. Where this factor is 
lacking, as in the case in South Africa, poor performance of the sector is noted. Secondly, 
patents remain an important intangible asset in this industry as discussed in section 2.6.2. The 
actual contribution of this parameter as discussed in section 4.5.2 is noted to be greater in the 
USA, Israel and Switzerland. The emerging markets (i.e India, Brazil and South Africa) are, 
however still struggling with valuation of IP. Furthermore, the local investment community in 
these markets is still averse to investing in companies, based on IP, versus the more common 
route of cash flow and tangible assets valuation. Thus, education of the investor community and 
creation of successful investments based on this approach are required to catalyze growth.  
 
It is clear from the work presented that the presence of multinational companies and established 
corporates is critical for good economic performance of this industry. This is exemplified by the 
number of M&A activities in the USA and Switzerland, where there is a high concentration of 
these companies more than any of the other markets studied. In addition, due to the small size 
and the illiquidity of the stock markets in these emerging markets compared to the developed 
markets, IPOs are generally not a viable option. Thus having a good presence of corporates in 
the sector, will provide exit options for investors. As discussed in section 2.7 SME’s in this 
sector will play an important role in job creation and contributing to the national GDP. Thus, 
taking into account the results presented in section 4.3 and the broader elements that contribute 
to a successful biotechnology industry, two (2) models are proposed based on a review of all of 
the elements presented in section 4.3. and 4.4. The models, presented in section 5.2.1 and 
5.2.2, could have a positive impact on the South African biotechnology industry. 
5.2.1 Recommended models 
It is clear from the work presented in the sections above that the South African government’s 
investment in this sector has yielded very little returns. Specifically, when compared to the 
Indian biotech sector investments by government, which are similar to that of South Africa, its 
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performance trails in comparison. India has a strong biotech sector which as reported in chapter 
4 above is projected to grow to 11.3 billion USD by 2017. Thus, the question remains that in 
addressing this poor performance, what funding models can be applied to improve the 
economic impact of the sector. 
5.2.1.1 Government-private sector matching funds linked to an 
incubator 
In late 2009, the Ministry of Finance and National Development and Reform Commission in 
China established the China Emerging Industry Start-up Investment Scheme to provide capital 
at the earliest stages of high technology company creation and development. The specific 
sector that this fund covers are those of strategic importance to China, such as biotechnology, 
life sciences, renewable energy, high end manufacturing, information technology, advanced 
materials and clean technology. The Ministry of Finance in China is the overall custodian of this 
fund, whereby in contributed 1.5 billion USD in 2009, and the required matching fund was 
contributed by local government and private sector, each contributing 1.5 billion USD. Through 
this fund, more than 70 early stage venture funds were established, creating a source of fund 
that technology start-ups could access, and also benefit from the private sector involvement in 
this fund (Frew et al., 2008).  
Thus, based on the Chinese case presented above, one of the models proposed in this thesis is 
the matching fund approach which will increase the capital resources dramatically and spur 
growth in this sector. In addition, the current Broad-Based Black Economic Empowerment 
(BBBEE) codes that require companies to support small business through enterprise 
development and supplier development could be linked to this fund from a monetary 
perspective. These funds could further be linked to an incubator where funded companies must 
be associated with an incubator to access these funds. This model allows for companies to not 
only receive financial support but also receive business advisory services offered by the 
incubator. In addition, the investor will be able to track the progress of the respective companies 
using processes already applied by the respective incubators. The pwc & Biominas (2011b) 
report of the Brazilian biotechnology industry indicated that about half of the companies in the 
sector and a majority of those that are generating income have been or are supported by an 
incubator, lending credence to this proposed model.  
5.2.1.2 Access patient capital and structure as a VC fund 
Since South Africa, unlike the USA and Switzerland does not have a high number of large 
corporates and multinational companies who conduct R&D in this country and would thus invest 
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in early stage companies for development of innovative products, an alternative funding model 
to ignite growth in this industry is would be access “patient” capital. This includes funds from 
pension funds, high net worth individuals, and government institutions. However, these funds 
would require to be structured like private equity or VC funds, with some alternations. These 
alterations would be, reducing the required internal rate of return (IRR) from the current 30% for 
VC funds to between 15-20% and also increasing the time to realizing the return. A positive 
aspect of most VC funds is the involvement of the fund managers in the enterprises 
management team, to support them in commercializing their enterprises. Thus, in structuring 
these funds, it will be imperative to ensure that the fund’s management team has sufficient 
experience to support the funded enterprise.  
This model would need to be supported by investment bankers who understand and have the 
international experience of investing in this sector. The critical aspect of this fund that will 
ensure that the patient capital is accessed is for the fund to targets SMEs that are developing 
products and services that will have significant socio-economic impact. The availability of VC 
funds to support start-ups has been one of main drivers of the success observed in USA, India 
and Israel. Thus, if replicated in SA, as proposed above, it is envisaged that growth and impact 
of the sector will be realized.  
5.3 Conclusions 
South African Biotechnology sector lags behind that of its emerging markets counterparts. 
Furthermore, it has indicated that in addition to the financing environment, which not broad 
enough, there are critical structural elements such as the involvement of universities, alliances 
with large corporates and the role of the stock market in raising capital that need to be 
addressed. There are additional challenges such as the lack of industry specific management 
skills, lack of understanding and experience in this biotechnology sector by the majority of 
investors, that all lead to this poor performance. What South Africa has done well is that its 
government has prioritized this sector under its Department of Science and Technology, has 
allocated a percentage of the national GDP similar to its emerging markets counterparts for 
R&D and has established specific institutions that are responsible for providing support and 
funding for enterprises in this sector. 
Thus, with all these efforts, it suggested that the South African government reviews its current 
funding models in an effort to realize a return on its investments. Two models are proposed in 
this work. Firstly government-private sector matching funds linked to an incubator and secondly, 
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increasing the pool of funds by accessing patient capital and structuring it as VC –type fund. 
The proposed models have been implemented elsewhere as discussed in section 5.2.1 and 
5.2.2 and have yielded positive returns. These returns have been in the form of an increase in 
the number of biotechnology companies, high survival rate, and high probability of revenue 
generation. Therefore, it is recommended that these models be applied in South Africa with the 
proposed alterations to drive growth of the sector. Furthermore, the South African government 
needs to have concerted efforts to attract industry players in this sector that would manufacture 
and produce biotech and pharmaceutical locally. As mentioned in section 4.5.3, the presence of 
large corporates that provide an avenue for investment exits and stimulating further growth. 
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Appendix 1: Structured interview questions for biotechnology funders 
in South Africa 
 
Conducted by: Boitumelo Semete-Makokotlela. 
1. Since when has the organisation been funding Biotech SME’s in South Africa? 
2. Who are the investors in this fund: 
- What proportion of these investors is government and what proportion is private 
sector? 
Companies funded 
3. How many companies has the institution funded since the fund started? 
4. How many of these companies are still in existence? 
5. Of those that are still operating, how many have: 
a) Positive cash flow and generate sustainable income? What is this income? 
b) What are the typical profit margins? 
c) Are there any that are publically listed? 
d) How many people do they employ? 
e) Have the companies managed to raised series B or venture capital funding? 
6. What are the reasons that have led to failure of those companies’ no longer in 
existences? 
7. Is there growth in the number of companies you fund? 
Nature of funding Instrument 
8. What is the type of finances provided by your institution? 
- What led to this model being the preferred one? 
9. Is the model sustainable and has it resulted in the expected output? 
10. What are the gaps with the model? 
Funding Environment 
11. What are elements that have led to the poor performance of the sector? 
12. What elements would lead to positive investment performance? 
Suggested funding model 
13. If you were to apply a different model to fund SMEs in this sector, what model would you 
apply and why? 
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